Celanese (CE) 10-Q 8 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 03, 2023
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-32410
Entity Registrant Name	CELANESE CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	98-0420726
Entity Address, Address Line One	222 W. Las Colinas Blvd., Suite 900N
Entity Address, City or Town	Irving
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75039-5421
City Area Code	972
Local Phone Number	443-4000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Small Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		108,855,167
Entity Central Index Key	0001306830
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false
Common Stock
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	CE
Security Exchange Name	NYSE
Senior Unsecured Notes Due 2025
Entity Information [Line Items]
Title of 12(b) Security	1.250% Senior Notes due 2025
Trading Symbol	CE /25
Security Exchange Name	NYSE
EUR Senior Unsecured Notes Due 2026
Entity Information [Line Items]
Title of 12(b) Security	4.777% Senior Notes due 2026
Trading Symbol	CE /26A
Security Exchange Name	NYSE
Senior Unsecured Notes Due 2027
Entity Information [Line Items]
Title of 12(b) Security	2.125% Senior Notes due 2027
Trading Symbol	CE /27
Security Exchange Name	NYSE
Senior Unsecured Notes Due 2028
Entity Information [Line Items]
Title of 12(b) Security	0.625% Senior Notes due 2028
Trading Symbol	CE /28
Security Exchange Name	NYSE
EUR Senior Unsecured Notes Due 2029
Entity Information [Line Items]
Title of 12(b) Security	5.337% Senior Notes due 2029
Trading Symbol	CE /29A
Security Exchange Name	NYSE

Unaudited Interim Consolidated

Unaudited Interim Consolidated Statement of Operations - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net sales	$ 2,723	$ 2,301	$ 8,371	$ 7,325
Cost of sales	(2,050)	(1,755)	(6,381)	(5,329)
Gross profit	673	546	1,990	1,996
Selling, general and administrative expenses	(244)	(184)	(803)	(555)
Amortization of intangible assets	(41)	(10)	(124)	(32)
Research and development expenses	(32)	(25)	(114)	(75)
Other (charges) gains, net	(17)	(15)	(50)	(15)
Foreign exchange gain (loss), net	0	(2)	21	(4)
Gain (loss) on disposition of businesses and assets, net	503	(2)	508	7
Operating profit (loss)	842	308	1,428	1,322
Equity in net earnings (loss) of affiliates	12	73	50	189
Non-operating pension and other postretirement employee benefit (expense) income	(1)	25	(2)	74
Interest expense	(178)	(154)	(542)	(237)
Refinancing expense	(7)	0	(7)	0
Interest income	12	34	27	36
Dividend income - equity investments	30	30	95	103
Other income (expense), net	4	5	2	4
Earnings (loss) from continuing operations before tax	714	321	1,051	1,491
Income tax (provision) benefit	236	(127)	215	(351)
Earnings (loss) from continuing operations	950	194	1,266	1,140
Earnings (loss) from operation of discontinued operations	(1)	0	(4)	(8)
Income tax (provision) benefit from discontinued operations	0	(1)	1	1
Earnings (loss) from discontinued operations	(1)	(1)	(3)	(7)
Net earnings (loss)	949	193	1,263	1,133
Net (earnings) loss attributable to noncontrolling interests	2	(2)	(1)	(6)
Net earnings (loss) attributable to Celanese Corporation	951	191	1,262	1,127
Amounts attributable to Celanese Corporation
Earnings (loss) from continuing operations	952	192	1,265	1,134
Earnings (loss) from discontinued operations	(1)	(1)	(3)	(7)
Net earnings (loss)	$ 951	$ 191	$ 1,262	$ 1,127
Earnings (loss) per common share - basic
Continuing operations - basic (in dollars per share)	$ 8.74	$ 1.77	$ 11.63	$ 10.47
Discontinued operations - basic (in dollars per share)	(0.01)	(0.01)	(0.03)	(0.07)
Net earnings (loss) - basic (in dollars per share)	8.73	1.76	11.60	10.40
Earnings (loss) per common share - diluted
Continuing operations - diluted (in dollars per share)	8.70	1.76	11.57	10.39
Discontinued operations - diluted (in dollars per share)	(0.01)	(0.01)	(0.03)	(0.07)
Net earnings (loss) - diluted (in dollars per share)	$ 8.69	$ 1.75	$ 11.54	$ 10.32
Weighted average shares - basic (in shares)	108,918,986	108,428,982	108,814,288	108,336,574
Weighted average shares - diluted (in shares)	109,439,486	109,065,970	109,338,040	109,158,832

Unaudited Interim Consolidate_2

Unaudited Interim Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net earnings (loss)	$ 949	$ 193	$ 1,263	$ 1,133
Other comprehensive income (loss), net of tax
Foreign currency translation gain (loss)	7	(49)	(181)	(201)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax	(17)	(11)	(13)	30
Pension and postretirement benefits	(1)	0	(1)	2
Total other comprehensive income (loss), net of tax	(11)	(60)	(195)	(169)
Total comprehensive income (loss), net of tax	938	133	1,068	964
Comprehensive (income) loss attributable to noncontrolling interests	2	(2)	(1)	(6)
Comprehensive income (loss) attributable to Celanese Corporation	$ 940	$ 131	$ 1,067	$ 958

Unaudited Consolidated Balance

Unaudited Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2023		Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 1,357		$ 1,508
Trade receivables - third party and affiliates	1,339		1,379
Non-trade receivables, net	570		675
Inventories	2,337		2,808
Other assets	284		241
Total current assets	5,887		6,611
Investments in affiliates	1,245		1,062
Property, plant and equipment (net of accumulated depreciation - 2023: $3,881; 2022: $3,687)	5,467		5,584
Operating lease right-of-use assets	395		413
Deferred income taxes	1,074		808
Other assets	535		547
Goodwill	6,991	[1]	7,142
Intangible assets, net	3,944		4,105
Total assets	25,538		26,272
Current Liabilities
Short-term borrowings and current installments of long-term debt - third party and affiliates	1,408		1,306
Trade payables - third party and affiliates	1,263		1,518
Other liabilities	927		1,201
Income taxes payable	18		43
Total current liabilities	3,616		4,068
Long-term debt, net of unamortized deferred financing costs	12,291		13,373
Deferred income taxes	1,223		1,242
Uncertain tax positions	276		322
Benefit obligations	396		411
Operating lease liabilities	334		364
Other liabilities	453		387
Commitments and Contingencies
Shareholders' Equity
Preferred stock, $0.01 par value, 100,000,000 shares authorized (2023 and 2022: 0 issued and outstanding)	0		0
Common stock, $0.0001 par value, 400,000,000 shares authorized (2023: 170,465,439 issued and 108,854,038 outstanding; 2022: 170,135,425 issued and 108,473,932 outstanding)	0		0
Treasury stock, at cost (2023: 61,611,401 shares; 2022: 61,661,493 shares)	(5,490)		(5,491)
Additional paid-in capital	386		372
Retained earnings	12,308		11,274
Accumulated other comprehensive income (loss), net	(713)		(518)
Total Celanese Corporation shareholders' equity	6,491		5,637
Noncontrolling interests	458		468
Total equity	6,949		6,105
Total liabilities and equity	$ 25,538		$ 26,272
[1]There were no accumulated impairment losses as of September 30, 2023.

Unaudited Consolidated Balanc_2

Unaudited Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Accumulated depreciation, depletion and amortization, property, plant, and equipment	$ 3,881	$ 3,687
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	100,000,000	100,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	170,465,439	170,135,425
Common stock, shares outstanding (in shares)	108,854,038	108,473,932
Treasury Stock, Common, Shares	61,611,401	61,661,493

Unaudited Interim Consolidate_3

Unaudited Interim Consolidated Statement Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss), Net	Noncontrolling Interests	Treasury Stock, Common
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Celanese Corporation stockholders' equity		$ 0	$ 333	$ 9,677	$ (329)		$ (5,492)
Balance as of the beginning of the period (in shares) at Dec. 31, 2021		108,023,735					61,736,289
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation, net of tax			23
Purchases of treasury stock (in shares)	0
Issuance of treasury stock under stock plans							$ 0
Issuance of treasury stock under stock plans (in shares)							(32,243)
Stock awards (in shares)		363,004
Stock awards		$ 0
Net earnings (loss) attributable to Celanese Corporation	$ 1,127			1,127
Common stock dividends				(220)
Other comprehensive income (loss), net of tax	(169)				(169)
Balance as of the beginning of the period, noncontrolling interest at Dec. 31, 2021						$ 348
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss) attributable to noncontrolling interests	6					6
Distributions/dividends to noncontrolling interests						(10)
Balance as of the end of the period, noncontrolling interest at Sep. 30, 2022						344
Balance as of the end of the period (in shares) at Sep. 30, 2022		108,386,739					61,704,046
Balance as of the end of the period at Sep. 30, 2022	5,294
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Celanese Corporation stockholders' equity		$ 0	344	10,466	(438)		$ (5,492)
Balance as of the beginning of the period (in shares) at Jun. 30, 2022		108,346,035					61,704,046
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation, net of tax			12
Issuance of treasury stock under stock plans							$ 0
Issuance of treasury stock under stock plans (in shares)							0
Stock awards (in shares)		40,704
Stock awards		$ 0
Net earnings (loss) attributable to Celanese Corporation	191			191
Common stock dividends				(73)
Other comprehensive income (loss), net of tax	(60)				(60)
Balance as of the beginning of the period, noncontrolling interest at Jun. 30, 2022						345
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss) attributable to noncontrolling interests	2					2
Distributions/dividends to noncontrolling interests						(3)
Balance as of the end of the period, noncontrolling interest at Sep. 30, 2022						344
Balance as of the end of the period (in shares) at Sep. 30, 2022		108,386,739					61,704,046
Balance as of the end of the period at Sep. 30, 2022	5,294
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Celanese Corporation stockholders' equity	4,950	$ 0	356	10,584	(498)		$ (5,492)
Celanese Corporation stockholders' equity	5,637	$ 0	372	11,274	(518)		$ (5,491)
Balance as of the beginning of the period (in shares) at Dec. 31, 2022		108,473,932					61,661,493
Balance as of the beginning of the period at Dec. 31, 2022	$ 6,105
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation, net of tax			14
Purchases of treasury stock (in shares)	0
Issuance of treasury stock under stock plans							$ 1
Issuance of treasury stock under stock plans (in shares)							(50,092)
Stock awards (in shares)		380,106
Stock awards		$ 0
Net earnings (loss) attributable to Celanese Corporation	$ 1,262			1,262
Common stock dividends				(228)
Other comprehensive income (loss), net of tax	(195)				(195)
Balance as of the beginning of the period, noncontrolling interest at Dec. 31, 2022	468					468
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss) attributable to noncontrolling interests	1					1
Distributions/dividends to noncontrolling interests						(11)
Balance as of the end of the period, noncontrolling interest at Sep. 30, 2023	458					458
Balance as of the end of the period (in shares) at Sep. 30, 2023		108,854,038					61,611,401
Balance as of the end of the period at Sep. 30, 2023	6,949
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Celanese Corporation stockholders' equity		$ 0	383	11,433	(702)		$ (5,490)
Balance as of the beginning of the period (in shares) at Jun. 30, 2023		108,847,435					61,611,401
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation, net of tax			3
Issuance of treasury stock under stock plans							$ 0
Issuance of treasury stock under stock plans (in shares)							0
Stock awards (in shares)		6,603
Stock awards		$ 0
Net earnings (loss) attributable to Celanese Corporation	951			951
Common stock dividends				(76)
Other comprehensive income (loss), net of tax	(11)				(11)
Balance as of the beginning of the period, noncontrolling interest at Jun. 30, 2023						464
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss) attributable to noncontrolling interests	(2)					(2)
Distributions/dividends to noncontrolling interests						(4)
Balance as of the end of the period, noncontrolling interest at Sep. 30, 2023	458					$ 458
Balance as of the end of the period (in shares) at Sep. 30, 2023		108,854,038					61,611,401
Balance as of the end of the period at Sep. 30, 2023	6,949
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Celanese Corporation stockholders' equity	$ 6,491	$ 0	$ 386	$ 12,308	$ (713)		$ (5,490)

Unaudited Interim Consolidate_4

Unaudited Interim Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating Activities
Net earnings (loss)	$ 1,263	$ 1,133
Adjustments to reconcile net earnings (loss) to net cash provided by (used in) operating activities
Depreciation, amortization and accretion	544	318
Asset impairments	9	12
Pension and postretirement net periodic benefit cost	10	(63)
Pension and postretirement contributions	(37)	(34)
Deferred income taxes, net	(282)	14
Gain (Loss) on Disposition of Property Plant Equipment	498	6
Stock-based compensation	36	47
Undistributed earnings in unconsolidated affiliates	20	(56)
Other, net	2	8
Operating cash provided by (used in) discontinued operations	(5)	(25)
Changes in operating assets and liabilities
Trade receivables - third party and affiliates, net	(16)	(61)
Inventories	373	(321)
Other assets	219	26
Trade payables - third party and affiliates	(171)	97
Other liabilities	(398)	189
Net cash provided by (used in) operating activities	1,069	1,278
Investing Activities
Capital expenditures on property, plant and equipment	(440)	(400)
Acquisitions, net of cash acquired	52	(14)
Proceeds from sale of businesses and assets, net	480	16
Other, net	(58)	(30)
Net cash provided by (used in) investing activities	34	(428)
Financing Activities
Net change in short-term borrowings with maturities of 3 months or less	(278)	(249)
Proceeds from short-term borrowings	452	0
Repayments of short-term borrowings	(603)	0
Proceeds from long-term debt	3,001	9,019
Repayments of long-term debt	(3,497)	(21)
Purchases of treasury stock, including related fees	0	(17)
Common stock dividends	(228)	(220)
Distributions to noncontrolling interests	(11)	(10)
Issuance cost of bridge facility	0	(63)
Other, net	(52)	(93)
Net cash provided by (used in) financing activities	(1,216)	8,346
Exchange rate effects on cash and cash equivalents	(38)	(61)
Net increase (decrease) in cash and cash equivalents	(151)	9,135
Cash and cash equivalents as of beginning of period	1,508	536
Cash and cash equivalents as of end of period	$ 1,357	$ 9,671

Description of the Company and

Description of the Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Company and Basis of Presentation	Description of the Company and Basis of Presentation Description of the Company Celanese Corporation and its subsidiaries (collectively, the "Company") is a global chemical and specialty materials company. The Company produces high performance engineered polymers that are used in a variety of high-value applications, as well as acetyl products, which are intermediate chemicals, for nearly all major industries. The Company also engineers and manufactures a wide variety of products essential to everyday living. The Company's broad product portfolio serves a diverse set of end-use applications including automotive, chemical additives, construction, consumer and industrial adhesives, consumer and medical, energy storage, filtration, food and beverage, paints and coatings, paper and packaging, performance industrial and textiles. Definitions In this Quarterly Report on Form 10-Q ("Quarterly Report"), the term "Celanese" refers to Celanese Corporation, a Delaware corporation, and not its subsidiaries. The term "Celanese U.S." refers to the Company's subsidiary, Celanese US Holdings LLC, a Delaware limited liability company, and not its subsidiaries. Basis of Presentation The unaudited interim consolidated financial statements for the three and nine months ended September 30, 2023 and 2022 contained in this Quarterly Report were prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for all periods presented and include the accounts of the Company, its majority owned subsidiaries over which the Company exercises control and, when applicable, variable interest entities in which the Company is the primary beneficiary. The unaudited interim consolidated financial statements and other financial information included in this Quarterly Report, unless otherwise specified, have been presented to separately show the effects of discontinued operations. In the opinion of management, the accompanying unaudited consolidated balance sheets and related unaudited interim consolidated statements of operations, comprehensive income (loss), cash flows and equity include all adjustments, consisting only of normal recurring items necessary for their fair presentation in conformity with U.S. GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission ("SEC"). These unaudited interim consolidated financial statements should be read in conjunction with the Company's consolidated financial statements as of and for the year ended December 31, 2022, filed on February 24, 2023 with the SEC as part of the Company's Annual Report on Form 10-K. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the entire year. In the ordinary course of business, the Company enters into contracts and agreements relative to a number of topics, including acquisitions, dispositions, joint ventures, supply agreements, product sales and other arrangements. The Company endeavors to describe those contracts or agreements that are material to its business, results of operations or financial position. The Company may also describe some arrangements that are not material but in which the Company believes investors may have an interest or which may have been included in a Form 8-K filing. Investors should not assume the Company has described all contracts and agreements relative to the Company's business in this Quarterly Report. For those consolidated ventures in which the Company owns or is exposed to less than 100% of the economics, the outside shareholders' interests are shown as noncontrolling interests. Estimates and Assumptions The preparation of unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of Net sales, expenses and allocated charges during the reporting period. Significant estimates pertain to impairments of goodwill, intangible assets and other long-lived assets, purchase price allocations, restructuring costs and other (charges) gains, net, income taxes, pension

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2023
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	Recent Accounting PronouncementsThere are no recent Accounting Standard Updates issued by the Financial Accounting Standards Board which are expected to materially impact the Company's financial position, operating results or financial disclosures.

Acquisitions, Dispositions and

Acquisitions, Dispositions and Plant Closures	9 Months Ended
	Sep. 30, 2023
Acquisitions, Dispositions and Plant Closures [Abstract]
Acquisitions, Dispositions and Plant Closures	Acquisitions, Dispositions and Plant Closures Acquisitions In November 2022, the Company acquired 100% ownership of entities and assets consisting of a majority of the Mobility & Materials business ("M&M") of DuPont de Nemours, Inc. ("DuPont") (the "M&M Acquisition") for a purchase price of $11.0 billion, subject to transaction adjustments, in an all-cash transaction. The Company acquired a global production network of 29 facilities, including compounding and polymerization, customer and supplier contracts and agreements, an intellectual property portfolio, including approximately 850 patents with associated technical and R&D assets, and approximately 5,000 employees across the manufacturing, technical and commercial organizations. This acquisition of M&M enhances the engineered materials product portfolio by adding new polymers, brands, product technology and backward integration in critical polymers, allowing the Company to accelerate growth in high-value applications including future mobility, connectivity and medical. The acquisition was accounted for as a business combination and the acquired operations are included in the Engineered Materials segment. The Company preliminarily allocated the purchase price of the acquisition to identifiable assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The purchase price allocation was based upon preliminary information and is subject to change if additional information about the facts and circumstances that existed at the acquisition date becomes available. The Company is in the ongoing process of conducting a valuation of the assets acquired and liabilities assumed related to the acquisition, including customer relationships, personal and real property and deferred taxes. The final fair value of the net assets acquired may result in adjustments to these assets and liabilities, including goodwill. During the measurement period to date, there were no adjustments that materially impacted the Company's goodwill initially recorded. The following unaudited pro forma financial information presents the consolidated results of operations as if the M&M Acquisition had occurred at the beginning of 2022. M&M's pre-acquisition results have been added to the Company's historical results. The pro forma results contained in the table below include adjustments for (i) increased depreciation expense as a result of acquisition date fair value adjustments, (ii) amortization of acquired intangibles, (iii) interest expense and amortization of debt issuance costs of $57 million and $400 million related to borrowings under the U.S. Term Loan Facility (defined below) and the issuance of Acquisition Notes (defined below) as if these had taken place at the beginning of 2022 for the three and nine months ended September 30, 2022, respectively, and (iv) net total step up of inventory amortized to Cost of sales of $131 million for the nine months ended September 30, 2022. There was no net total step up of inventory amortized to Cost of sales for the three months ended September 30, 2022. These pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the results of operations as they would have been had the acquisitions occurred on the assumed dates, nor are they necessarily an indication of future operating results. The unaudited consolidated pro forma results are as follows: Three Months Ended Nine Months Ended (In $ millions) Proforma Net sales 3,141 9,965 Proforma Earnings (loss) from continuing operations before tax 163 760 Nutrinova Joint Venture On September 27, 2023, the Company formed a food ingredients joint venture with Mitsui & Co., Ltd. ("Mitsui") under the name Nutrinova. The Company contributed receivables, inventory, property, plant and equipment, certain other assets, other liabilities, technology and employees of its food ingredients business while retaining a 30% interest in the joint venture. Mitsui acquired the remaining 70% interest in the food ingredients business for a purchase price of $503 million, subject to transaction adjustments. The Company is accounting for its interest in the joint venture as an equity method investment, and its portion of the results will continue to be included in the Engineered Materials segment. A gain on the transaction of $508 million is included in Gain (loss) on disposition of businesses and assets, net in the unaudited interim consolidated statements of operations for three and nine months ended September 30, 2023. Korea Engineering Plastics Co. Restructuring In April 2022, the Company completed the restructuring of Korea Engineering Plastics Co. ("KEPCO"), a joint venture owned 50% by the Company and 50% by Mitsubishi Gas Chemical Company, Inc. KEPCO was first formed in 1987 to manufacture and market polyoxymethylene ("POM") in Asia, with a particular focus on serving domestic demand in South Korea. KEPCO will now focus solely on manufacturing and supplying high quality products to its shareholders, who will independently market them globally. As part of the restructuring of KEPCO, the Company paid KEPCO $5 million and will pay 5 equal annual installments of €24 million on October 1 of each year beginning in 2022. This resulted in an increase to the Company's investment in KEPCO of $134 million. The Company's joint venture partner will make similar payments to KEPCO. The restructuring did not result in a change in ownership percentage of KEPCO, nor a change in control, and KEPCO will continue to be accounted for as an equity method investment.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories As of As of (In $ millions) Finished goods 1,573 1,820 Work-in-process 169 202 Raw materials and supplies 595 786 Total 2,337 2,808

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, net	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net Goodwill Engineered Acetyl Chain Total (In $ millions) As of December 31, 2022 6,775 367 7,142 Acquisitions ( Note 3 ) (24) — (24) Disposition (1) (80) — (80) Exchange rate changes (45) (2) (47) As of September 30, 2023 (2) 6,626 365 6,991 ______________________________ (1) Related to the formation of the Nutrinova joint venture ( Note 3 ). (2) There were no accumulated impairment losses as of September 30, 2023. The Company assesses the recoverability of the carrying amount of its reporting unit goodwill either qualitatively or quantitatively annually during the third quarter of its fiscal year using June 30 balances or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be fully recoverable. In connection with the Company's annual goodwill impairment assessment, the Company did not record an impairment loss to goodwill during the nine months ended September 30, 2023 as the estimated fair value for each of the Company's reporting units exceeded the carrying amount of the underlying assets by a substantial margin. Intangible Assets, Net Finite-lived intangible assets are as follows: Licenses Customer- Developed Covenants Total (In $ millions) Gross Asset Value As of December 31, 2022 42 2,455 601 55 3,153 Disposition (1) — (58) — — (58) Exchange rate changes (2) (23) (10) — (35) As of September 30, 2023 40 2,374 591 55 3,060 Accumulated Amortization As of December 31, 2022 (39) (567) (50) (40) (696) Amortization — (93) (30) (1) (124) Disposition (1) — 58 — — 58 Exchange rate changes 2 10 — — 12 As of September 30, 2023 (37) (592) (80) (41) (750) Net book value 3 1,782 511 14 2,310 ______________________________ (1) Related to the formation of the Nutrinova joint venture ( Note 3 ). Indefinite-lived intangible assets are as follows: Trademarks (In $ millions) As of December 31, 2022 1,648 Disposition (1) (14) Exchange rate changes — As of September 30, 2023 1,634 ______________________________ (1) Related to the formation of the Nutrinova joint venture ( Note 3 ). The Company assesses the recoverability of the carrying amount of its indefinite-lived intangible assets either qualitatively or quantitatively annually during the third quarter of its fiscal year using June 30 balances or whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. In connection with the Company's annual indefinite-lived intangible assets impairment assessment, the Company did not record an impairment loss to indefinite-lived intangible assets during the nine months ended September 30, 2023 as the estimated fair value of each of the Company's indefinite-lived intangible assets exceeded the carrying value of the underlying assets by a substantial margin. During the nine months ended September 30, 2023, the Company did not renew or extend any intangible assets. Estimated amortization expense for the succeeding five fiscal years is as follows: (In $ millions) 2024 161 2025 161 2026 160 2027 160 2028 160

Current Other Liabilities

Current Other Liabilities	9 Months Ended
	Sep. 30, 2023
Other Liabilities, Current [Abstract]
Current Other Liabilities	Current Other Liabilities As of As of (In $ millions) Benefit obligations ( Note 8 ) 25 25 Customer rebates 79 101 Derivatives ( Note 12 ) 46 63 Interest ( Note 7 ) 137 265 Legal ( Note 14 ) 25 21 Operating leases 88 83 Restructuring ( Note 18 ) 21 6 Salaries and benefits 149 151 Sales and use tax/foreign withholding tax payable 104 108 Investment in affiliates 91 79 Other (1) 162 299 Total 927 1,201 ____________________________ (1) Includes $27 million and $166 million payable to DuPont related to the M&M Acquisition and transition activities as of September 30, 2023 and December 31, 2022, respectively.

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	Debt As of As of (In $ millions) Short-Term Borrowings and Current Installments of Long-Term Debt - Third Party and Affiliates Current installments of long-term debt 1,061 506 Short-term borrowings, including amounts due to affiliates (1) 142 500 Revolving credit facilities (2) 205 300 Total 1,408 1,306 ______________________________ (1) The weighted average interest rate was 2.9% and 5.8% as of September 30, 2023 and December 31, 2022, respectively. (2) The weighted average interest rate was 3.4% and 5.8% as of September 30, 2023 and December 31, 2022, respectively. As of As of (In $ millions) Long-Term Debt Senior unsecured notes due 2023, interest rate of 1.125% — 480 Senior unsecured notes due 2024, interest rate of 3.500% 473 499 Senior unsecured notes due 2024, interest rate of 5.900% 527 2,000 Senior unsecured notes due 2025, interest rate of 1.250% 318 320 Senior unsecured notes due 2025, interest rate of 6.050% 1,000 1,750 Senior unsecured term loan due 2025 (1) — 750 Senior unsecured notes due 2026, interest rate of 1.400% 400 400 Senior unsecured notes due 2026, interest rate of 4.777% 1,060 1,067 Senior unsecured notes due 2027, interest rate of 2.125% 528 531 Senior unsecured notes due 2027, interest rate of 6.165% 2,000 2,000 Senior unsecured term loan due 2027 (1) 1,000 1,000 Senior unsecured notes due 2028, interest rate of 0.625% 529 533 Senior unsecured notes due 2028, interest rate of 6.350% 1,000 — Senior unsecured notes due 2029, interest rate of 5.337% 529 533 Senior unsecured notes due 2029, interest rate of 6.330% 750 750 Senior unsecured notes due 2030, interest rate of 6.550% 999 — Senior unsecured notes due 2032, interest rate of 6.379% 1,000 1,000 Senior unsecured notes due 2033, interest rate of 6.700% 1,000 — Pollution control and industrial revenue bonds due at various dates through 2030 (2) 163 164 Bank loans due at various dates through 2030 (3) 5 4 Obligations under finance leases due at various dates through 2054 150 172 Subtotal 13,431 13,953 Unamortized deferred financing costs (4) (79) (74) Current installments of long-term debt (1,061) (506) Total 12,291 13,373 ______________________________ (1) The interest rate was 6.930% and 5.934% as of September 30, 2023 and December 31, 2022, respectively. (2) Interest rates range from 4.05% and 5.00%. (3) The weighted average interest rate was 2.6% and 1.3% as of September 30, 2023 and December 31, 2022, respectively. (4) Related to the Company's long-term debt, excluding obligations under finance leases. Senior Credit Facilities In March 2022, Celanese, Celanese U.S. and certain subsidiaries entered into a term loan credit agreement (the "March 2022 U.S. Term Loan Credit Agreement"), pursuant to which lenders provided a tranche of delayed-draw term loans due 364 days from issuance in an amount equal to $500 million (the "364-day Term Loans") and a tranche of delayed-draw term loans due 5 years from issuance in an amount equal to $1.0 billion (the "5-year Term Loans"). In September 2022, Celanese, Celanese U.S. and certain subsidiaries entered into an additional term loan credit agreement (the "September 2022 U.S. Term Loan Credit Agreement" and, together with the March 2022 U.S. Term Loan Credit Agreement, the "U.S. Term Loan Credit Agreements"), pursuant to which lenders provided delayed-draw term loans due 3 years from issuance in an amount equal to $750 million (the "3-year Term Loans" and collectively with the 364-day Term Loans and the 5-year Term Loans, the "U.S. Term Loan Facility"). The U.S. Term Loan Facility was fully drawn during the three months ended December 31, 2022. Also in March 2022, Celanese, Celanese U.S. and certain subsidiaries entered into a new revolving credit agreement (the "U.S. Revolving Credit Agreement" and, together with the March 2022 U.S. Term Loan Credit Agreement, the "U.S. Credit Agreements") consisting of a $1.75 billion senior unsecured revolving credit facility (with a letter of credit sublimit), maturing in 2027 (the "U.S. Revolving Credit Facility"). On February 21, 2023, the Company amended certain covenants in the U.S. Credit Agreements, including financial ratio maintenance covenants. The U.S. Credit Agreements are guaranteed by Celanese, Celanese U.S. and domestic subsidiaries together representing substantially all of the Company's U.S. assets and business operations (the "Subsidiary Guarantors"). The Subsidiary Guarantors are listed in Exhibit 22.1 to this Quarterly Report. On January 4, 2023, Celanese (Shanghai) International Trading Co., Ltd ("CSIT"), a fully consolidated subsidiary, entered into a restatement of an existing credit facility agreement (the "China Revolving Credit Agreement") to upsize and modify the facility thereunder to consist of an aggregate CNY1.75 billion uncommitted senior unsecured revolving credit facility available under two tranches (with overdraft, bank guarantee and documentary credit sublimits) (the "China Revolving Credit Facility"). Obligations bear interest at certain fixed and floating rates. The China Revolving Credit Agreement is guaranteed by Celanese U.S. On January 6, 2023, CSIT entered into a senior unsecured working capital loan contract for CNY800 million (the "China Working Capital Term Loan Agreement," together with the China Revolving Credit Agreement, the "China Credit Agreements," and the China Credit Agreements together with the U.S. Credit Agreements, the "Global Credit Agreements"), payable 12 months from withdrawal date and bearing interest at 0.5% less than certain interbank rates. The loan under the China Working Capital Term Loan Agreement was fully drawn on January 10, 2023 and is supported by a letter of comfort from the Company. The Company expects that the China Credit Agreements will facilitate its efficient repatriation of cash to the U.S. to repay debt and effectively redomicile a portion of its U.S. debt to China at a lower average interest rate. The Company's debt balances and amounts available for borrowing under its senior unsecured revolving credit facilities are as follows: As of (In $ millions) U.S. Revolving Credit Facility Borrowings outstanding — Available for borrowing 1,750 China Revolving Credit Facility Borrowings outstanding 205 Available for borrowing 35 Senior Notes The Company has outstanding senior unsecured notes, issued in public offerings registered under the Securities Act of 1933, as amended (the "Securities Act") (collectively, the "Senior Notes"). The Senior Notes were issued by Celanese U.S. and are guaranteed on a senior unsecured basis by Celanese and the Subsidiary Guarantors. Celanese U.S. may redeem some or all of each of the Senior Notes, prior to their respective maturity dates, at a redemption price of 100% of the principal amount, plus a "make-whole" premium as specified in the applicable indenture, plus accrued and unpaid interest, if any, to the redemption date. In July 2022, Celanese U.S. completed an offering of $7.5 billion aggregate principal amount of notes of various maturities in a public offering registered under the Securities Act (the "Acquisition USD Notes"). In July 2022, Celanese U.S. completed an offering of €1.5 billion in aggregate principal amount of euro-denominated senior unsecured notes due in 2026 and 2029 in a public offering registered under the Securities Act (collectively, the "Acquisition Euro Notes" and together with the Acquisition USD Notes, the "Acquisition Notes"). Certain of the Acquisition Notes were issued at a discount to par, which is being amortized to Interest expense in the unaudited interim consolidated statements of operations over the terms of the applicable Acquisition Notes. Fees and expenses of the offering of the Acquisition Notes, inclusive of underwriting discounts, were $65 million. On August 24, 2023, Celanese U.S. completed a public offering registered under the Securities Act of senior unsecured notes as follows (collectively, the "2023 Offering"): Maturity Date Aggregate Principal Discount to Par Interest Rate (In $ millions) November 15, 2028 1,000 99.986% 6.350% November 15, 2030 999 99.950% 6.550% November 15, 2033 1,000 99.992% 6.700% Deferred financing costs related to the 2023 Offering, including underwriting discounts, were $26 million for the three and nine months ended September 30, 2023 and are being amortized to Interest expense in the unaudited interim consolidated statements of operations over the terms of the applicable notes. On August 25, 2023, Celanese U.S. completed a cash tender offer for $2.25 billion in aggregate principal amount (the "Tender Offer") as follows: Maturity Date Aggregate Principal Amount Tendered Purchase price per $1,000 principal amount Total Tender Offer Consideration Accrued and Unpaid Interest (In $ millions) (In $ millions) June 30, 2024 1,473 $ 999.92 1,473 12 March 15, 2025 750 $ 1,002.85 752 20 April 30, 2024 27 $ 983.95 27 — The net proceeds from the 2023 Offering were used (i) to fund the Tender Offer and (ii) for repayment of other outstanding indebtedness, including the payment in full of the 364-day Term Loans and the 3-year Term Loans. Refinancing expense in the unaudited interim consolidated statements of operations includes fees and expenses related to the Tender Offer, including accelerated amortization of deferred financing costs associated with the principal amounts tendered, was $7 million for the three and nine months ended September 30, 2023. Accounts Receivable Purchasing Facility On June 1, 2023, the Company entered into an amendment to the amended and restated receivables purchase agreement (the "Amended Receivables Purchase Agreement") under its U.S. accounts receivable purchasing facility among certain of the Company's subsidiaries, its wholly-owned, "bankruptcy remote" special purpose subsidiary ("SPE") and certain global financial institutions ("Purchasers"). The Amended Receivables Purchase Agreement extends the term of the accounts receivable purchasing facility such that the SPE may sell certain receivables until June 18, 2025. Under the Amended Receivables Purchase Agreement, transfers of U.S. accounts receivable from the SPE are treated as sales and are accounted for as a reduction in accounts receivable because the agreement transfers effective control over and risk related to the U.S. accounts receivable to the SPE. The Company and related subsidiaries have no continuing involvement in the transferred U.S. accounts receivable, other than collection and administrative responsibilities and, once sold, the U.S. accounts receivable are no longer available to satisfy creditors of the Company or the related subsidiaries. These sales are transacted at 100% of the face value of the relevant U.S. accounts receivable, resulting in derecognition of the U.S. accounts receivables from the Company's unaudited consolidated balance sheet. The Company de-recognized $1.0 billion and $1.1 billion of accounts receivable under this agreement for the nine months ended September 30, 2023 and year ended December 31, 2022, respectively, and collected $977 million and $1.1 billion of accounts receivable sold under this agreement during the same periods. Unsold U.S. accounts receivable of $110 million were pledged by the SPE as collateral to the Purchasers as of September 30, 2023. Factoring and Discounting Agreements The Company has factoring agreements in Europe and Singapore with financial institutions to sell 100% and 90% of certain accounts receivable, respectively, on a non-recourse basis. These transactions are treated as sales and are accounted for as reductions in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyer. The Company has no continuing involvement in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. The Company de-recognized $305 million and $320 million of accounts receivable under these factoring agreements for the nine months ended September 30, 2023 and year ended December 31, 2022, respectively, and collected $294 million and $325 million of accounts receivable sold under these factoring agreements during the same periods. Covenants The Company's material financing arrangements contain customary covenants, such as events of default and change of control provisions, and in the case of the U.S. Credit Agreements the maintenance of certain financial ratios (subject to adjustment following certain qualifying acquisitions and dispositions, as set forth in the U.S. Credit Agreements, as amended). Failure to comply with these covenants, or the occurrence of any other event of default, could result in acceleration of the borrowings and other financial obligations. The Company is in compliance with the covenants in its material financing arrangements as of September 30, 2023.

Benefit Obligations

Benefit Obligations	9 Months Ended
	Sep. 30, 2023
Retirement Benefits [Abstract]
Benefit Obligations	Benefit Obligations The components of net periodic benefit cost are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Pension Post-retirement Pension Post-retirement Pension Post-retirement Pension Post-retirement (In $ millions) Service cost 2 — 3 1 8 — 10 1 Interest cost 32 1 17 — 98 2 50 1 Expected return on plan assets (32) — (42) — (98) — (125) — Total 2 1 (22) 1 8 2 (65) 2 Benefit obligation funding is as follows: As of Total Expected 2023 (In $ millions) Cash contributions to defined benefit pension plans 20 27 Benefit payments to nonqualified pension plans 15 18 Benefit payments to other postretirement benefit plans 2 4 The Company's estimates of its U.S. defined benefit pension plan contributions reflect the provisions of the Pension Protection Act of 2006. Pension and postretirement benefit plan balances recognized in the unaudited consolidated balance sheets consist of the following: As of September 30, 2023 As of December 31, 2022 Pension Post-retirement Pension Post-retirement (In $ millions) Noncurrent Other assets 167 — 160 — Current Other liabilities (21) (3) (21) (3) Benefit obligations (357) (35) (372) (35) Net amount recognized (211) (38) (233) (38)

Environmental

Environmental	9 Months Ended
	Sep. 30, 2023
Environmental Remediation Obligations [Abstract]
Environmental	Environmental The Company is subject to environmental laws and regulations worldwide that impose limitations on the discharge of pollutants into the air and water, establish standards for the treatment, storage and disposal of solid and hazardous wastes, and impose record keeping and notification requirements. Failure to timely comply with these laws and regulations may expose the Company to penalties. The Company believes that it is in substantial compliance with all applicable environmental laws and regulations and engages in an ongoing process of updating its controls to mitigate compliance risks. The Company is also subject to retained environmental obligations specified in various contractual agreements arising from the divestiture of certain businesses by the Company or one of its predecessor companies. The components of environmental remediation liabilities are as follows: As of As of (In $ millions) Demerger obligations ( Note 14 ) 17 20 Divestiture obligations ( Note 14 ) 13 14 Active sites 19 21 U.S. Superfund sites 8 10 Other environmental remediation liabilities 2 2 Total 59 67 Remediation Due to its industrial history and through retained contractual and legal obligations, the Company has the obligation to remediate specific areas on its own sites as well as on divested, demerger, orphan or U.S. Superfund sites (defined below). In addition, as part of the demerger agreement between the Company and Hoechst AG ("Hoechst"), a specified portion of the responsibility for environmental liabilities from a number of Hoechst divestitures was transferred to the Company ( Note 14 ). Certain of these sites, at which the Company maintains continuing involvement, were and continue to be designated as discontinued operations when closed. The Company provides for such obligations when the event of loss is probable and reasonably estimable. The Company believes that environmental remediation costs will not have a material adverse effect on the financial position of the Company, but may have a material adverse effect on the results of operations or cash flows in any given period. U.S. Superfund Sites In the U.S., the Company may be subject to substantial claims brought by U.S. federal or state regulatory agencies or private individuals pursuant to statutory authority or common law. In particular, the Company has a potential liability under the U.S. Federal Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, and related state laws (collectively referred to as "Superfund") for investigation and cleanup costs at certain sites. At most of these sites, numerous companies, including the Company, or one of its predecessor companies, have been notified that the U.S. Environmental Protection Agency ("EPA"), state governing bodies or private individuals consider such companies to be potentially responsible parties ("PRP") under Superfund or related laws. The proceedings relating to these sites are in various stages. The cleanup process has not been completed at most sites, and the status of the insurance coverage for some of these proceedings is uncertain. Consequently, the Company cannot accurately determine its ultimate liability for investigation or cleanup costs at these sites. As events progress at each site for which it has been named a PRP, the Company accrues any probable and reasonably estimable liabilities. In establishing these liabilities, the Company considers the contaminants of concern, the potential impact thereof, the relationship of the contaminants of concern to its current and historic operations, its shipment of waste to a site, its percentage of total waste shipped to the site, the types of wastes involved, the conclusions of any studies, the magnitude of any remedial actions that may be necessary and the number and viability of other PRPs. Often the Company joins with other PRPs to sign joint defense agreements that settle, among PRPs, each party's percentage allocation of costs at the site. Although the ultimate liability may differ from the estimate, the Company routinely reviews the liabilities and revises the estimate, as appropriate, based on the most current information available. One such site is the Diamond Alkali Superfund Site, which is comprised of a number of sub-sites, including the Lower Passaic River Study Area ("LPRSA"), which is the lower 17-mile stretch of the Passaic River ("Lower Passaic River Site"), and the Newark Bay Study Area. The Company and 70 other companies are parties to a May 2007 Administrative Order on Consent with the EPA to perform a Remedial Investigation/Feasibility Study ("RI/FS") at the Lower Passaic River Site in order to identify the levels of contaminants and potential cleanup actions, including the potential migration of contaminants between the LPRSA and the Newark Bay Area. In March 2016, the EPA issued its final Record of Decision concerning the remediation of the lower 8.3 miles of the Lower Passaic River Site ("Lower 8.3 Miles"). Pursuant to the EPA's Record of Decision, the Lower 8.3 Miles must be dredged bank to bank and an engineered cap must be installed at an EPA estimated cost of approximately $1.4 billion. In September 2021, the EPA issued a Record of Decision selecting an interim remedial plan for the upper 9 miles of the Lower Passaic River ("Upper 9 Miles"). Pursuant to the EPA's Record of Decision, targeted dredging will be conducted in the Upper 9 Miles to address surface sediments with elevated contamination followed by the installation of an engineered cap at an EPA estimated cost of $441 million. The Company owned and/or operated facilities in the vicinity of the Lower 8.3 Miles, but has found no evidence that it contributed any of the contaminants of concern to the Passaic River. In June 2018, Occidental Chemical Corporation ("OCC"), the successor to the Diamond Alkali Company, sued a subsidiary of the Company and 119 other parties alleging claims for joint and several damages, contribution and declaratory relief under Section 107 and 113 of Superfund for costs to clean up the LPRSA portion of the Diamond Alkali Superfund Site, Occidental Chemical Corporation v. 21st Century Fox America, Inc., et al, No. 2:18-CV-11273 (MCA) (LDW) (U.S. District Court New Jersey) (the "2018 OCC Lawsuit"), alleging that each of the defendants owned or operated a facility that contributed contamination to the LPRSA. With respect to the Company, the 2018 OCC lawsuit is limited to the former Celanese facility that Essex County, New Jersey has agreed to indemnify the Company for and does not change the Company's estimated liability for LPRSA cleanup costs. Separately, the United States lodged a Consent Decree in U.S. District Court for the District of New Jersey on December 16, 2022 that will resolve the Company's liability (and that of more than 80 other settling defendants) to the EPA for costs to clean up both the Lower 8.3 Miles and Upper 9 Miles of the Lower Passaic River Site in exchange for a collective payment of $150 million, United States v. Alden Leeds, Inc., No. 2:22-7326 (MCA) (LDW) (U.S. District Court New Jersey) ("Consent Decree Action"). The Consent Decree also will provide the Company protection from contribution claims by others for costs incurred to clean up both the Lower 8.3 Miles and Upper 9 Miles of the Lower Passaic River Site. The Company's proposed payment toward the $150 million collective settlement payment is not material to the Company's results of operations, cash flows or financial position. The Consent Decree is still subject to public comment and court approval. On March 7, 2023, the U.S. District Court for the District of New Jersey entered an order staying and administratively terminating the 2018 OCC Lawsuit, pending resolution of the request for judicial approval of the Consent Decree in the Consent Decree Action. On March 24, 2023, OCC filed a new lawsuit against 40 parties, including a subsidiary of the Company, seeking to recover costs for remedial design work the EPA has ordered OCC to undertake for a portion of the LPRSA at an estimated cost of $71 million, Occidental Chemical Corporation v. Givaudan Fragrances Corporation, No. 2:23-cv-1699 (U.S. District Court New Jersey) (the "2023 OCC Lawsuit"). Like the earlier lawsuit, the 2023 OCC Lawsuit concerns the facility Essex County, New Jersey purchased and for which Essex County, New Jersey has agreed to defend and indemnify the Company. This new lawsuit does not change the Company's estimated liability for LPRSA cleanup costs. The Company will continue to vigorously defend these matters and continues to believe that its ultimate allocable share of the cleanup costs with respect to the Lower Passaic River Site, previously estimated at less than 1%, will not be material. Other Environmental Matters In April 2022, a methanol leak on a pipeline to the Company's Bishop, Texas facility was discovered. The release has been contained, the leak has been repaired and the pipeline has resumed operation. The Company promptly disclosed the incident to state and federal authorities, including the Texas Commission on Environmental Quality and the EPA, and remediation activities are now completed. While the Company has not received a notice of violation nor been assessed any fines or penalties to date, the Company recorded a reserve in Other current liabilities based on anticipated clean-up costs and possible penalties to state or federal authorities. The Company does not believe that resolution of this matter will have a material impact on its financial condition or results of operations.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Shareholders' Equity Common Stock The Company's Board of Directors follows a policy of declaring, subject to legally available funds, a quarterly cash dividend on each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), unless the Company's Board of Directors, in its sole discretion, determines otherwise. The amount available to the Company to pay cash dividends is not currently restricted by its existing Global Credit Agreements and its indentures governing its senior unsecured notes. Any decision to declare and pay dividends in the future will be made at the discretion of the Company's Board of Directors and will depend on, among other things, the results of operations, cash requirements, financial condition, contractual restrictions and other factors that the Company's Board of Directors may deem relevant. The Company declared a quarterly cash dividend of $0.70 per share on its Common Stock on October 18, 2023, amounting to $76 million. The cash dividend will be paid on November 13, 2023 to holders of record as of October 30, 2023. Treasury Stock The Company's Board of Directors authorizes repurchases of Common Stock from time to time. These authorizations give management discretion in determining the timing and conditions under which shares may be repurchased. This repurchase program does not have an expiration date. Total From Shares repurchased 69,324,429 Average purchase price per share $ 83.71 Shares repurchased (in $ millions) $ 5,803 Aggregate Board of Directors repurchase authorizations during the period (in $ millions) $ 6,866 The purchase of treasury stock reduces the number of shares outstanding. The repurchased shares may be used by the Company for compensation programs utilizing the Company's stock and other corporate purposes. The Company accounts for treasury stock using the cost method and includes treasury stock as a component of shareholders' equity. The Company did not repurchase any Common Stock during the nine months ended September 30, 2023 or 2022. Other Comprehensive Income (Loss), Net Three Months Ended September 30, 2023 2022 Gross Income Net Gross Income Net (In $ millions) Foreign currency translation gain (loss) 34 (27) 7 3 (52) (49) Gain (loss) on derivative hedges (21) 4 (17) (15) 4 (11) Pension and postretirement benefits gain (loss) (1) — (1) — — — Total 12 (23) (11) (12) (48) (60) Nine Months Ended September 30, 2023 2022 Gross Income Net Gross Income Net (In $ millions) Foreign currency translation gain (loss) (184) 3 (181) (119) (82) (201) Gain (loss) on derivative hedges (18) 5 (13) 37 (7) 30 Pension and postretirement benefits gain (loss) (2) 1 (1) 2 — 2 Total (204) 9 (195) (80) (89) (169) Adjustments to Accumulated other comprehensive income (loss), net, are as follows: Foreign Gain (Loss) on Derivative Hedges ( Note 12 ) Pension and Postretirement Benefits Gain (Loss) ( Note 8 ) Accumulated (In $ millions) As of December 31, 2022 (488) (22) (8) (518) Other comprehensive income (loss) before reclassifications (184) 20 (2) (166) Amounts reclassified from accumulated other comprehensive income (loss) — (38) — (38) Income tax (provision) benefit 3 5 1 9 As of September 30, 2023 (669) (35) (9) (713)

Other (Charges) Gains, Net

Other (Charges) Gains, Net	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Other (Charges) Gains, Net	Other (Charges) Gains, Net Three Months Ended Nine Months Ended 2023 2022 2023 2022 (In $ millions) Restructuring (1) (7) (3) (40) (3) Asset impairments (9) (12) (9) (12) Plant/office closures (1) — (1) — Total (17) (15) (50) (15) ______________________________ (1) Includes employee termination benefits primarily related to Company-wide business optimization projects during the three and nine months ended September 30, 2023. The changes in the restructuring liabilities by business segment are as follows: Engineered Acetyl Other Total (In $ millions) Employee Termination Benefits As of December 31, 2022 4 1 1 6 Additions 34 1 5 40 Cash payments (20) (1) (4) (25) As of September 30, 2023 18 1 2 21

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Three Months Ended Nine Months Ended 2023 2022 2023 2022 (In percentages) Effective income tax rate (33) 40 (20) 24 The effective income tax rate for the three and nine months ended September 30, 2023 was lower compared to the same periods in 2022, primarily due to deferred tax benefits of $293 million from the relocation of certain intangible assets to align with the foreign operations acquired in the M&M Acquisition, differences in the tax and U.S. GAAP gain from the formation of the Nutrinova joint venture, decreased earnings in high taxed jurisdictions related to current demand conditions and a decrease in valuation allowances on U.S. foreign tax credit carryforwards due to revised forecasts of foreign sourced income and expenses during the carryforward period. In December 2017, the Tax Cuts and Jobs Act (the "TCJA") was enacted and was effective January 1, 2018. The U.S. Treasury has issued various final and proposed regulatory packages supplementing the TCJA provisions since 2018. There have been no material proposed or final regulatory packages during the three months ended September 30, 2023. In August 2022, the Inflation Reduction Act (the "IRA") was enacted and included a 1% excise tax on share repurchases in excess of $1 million, and a corporate minimum tax of 15% on adjusted book earnings. The corporate minimum tax paid is creditable in future years to the extent that regular tax liability exceeds the minimum tax in any given year. The Company does not expect these provisions and any newly issued administrative guidance to have a material impact to future income tax expense. The IRA also provides various beneficial credits for energy efficient related manufacturing, transportation and fuels, hydrogen/carbon recapture and renewable energy, which the Company is evaluating in regards to planned projects. The Company will continue to monitor the expected impacts of any new guidance on the Company's filing positions and will record the impacts as discrete income tax expense or benefit in the period the guidance is finalized or becomes effective. Due to the TCJA and uncertainty as to future foreign source income, the Company previously recorded a valuation allowance on a substantial portion of its foreign tax credit carryforwards. The Company is currently evaluating tax planning strategies to enable the use of the Company's foreign tax credit carryforwards that may decrease the Company's effective tax rate in future periods as the valuation allowance is reversed. The Company's tax returns have been under joint audit for the years 2013 through 2015 by the United States, Netherlands and Germany (the "Authorities"). In September 2021, the Company received a draft joint audit report proposing adjustments to transfer pricing and the reallocation of income between the related jurisdictions. The Company and the Authorities were unable to reach an agreement jointly and therefore the audits continued on a separate jurisdictional basis. In the fourth quarter of 2022, the Company mutually concluded settlement discussions with the Dutch tax authorities. The Company is engaged in discussions with the other authorities regarding the ongoing examinations and will evaluate all additional potential remedies as the discussions progress. In addition, the Company's income tax returns in Mexico are under audit for the year 2018, and in Canada for the years 2016 through 2022. In August 2023, the Company negotiated a partial settlement with the Mexico tax authorities for its audit for the year 2018. The partial settlement did not have a material impact on income tax expense in the unaudited interim consolidated statements of operations for the three and nine months ended September 30, 2023. In September 2023, the Canadian tax authorities opened tax audits for the years 2019 through 2022, and the audits are in the preliminary stages. The Company is in ongoing discussions regarding the audit findings with the Canadian tax authorities for the years 2016 through 2018 and does not expect a material impact to income tax expense. As of September 30, 2023, the Company believes that an adequate provision for income taxes has been made for all open tax years related to the examinations by government authorities. However, the outcome of tax audits cannot be predicted with certainty. If any issues raised in the audits described above are resolved in a manner inconsistent with the Company's expectations or the Company is unsuccessful in defending its positions, the Company could be required to adjust its provision for income taxes in the period such resolution occurs. If required, any such adjustments could be material to the statements of operations and cash flows in the period(s) recorded.

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Derivative Financial Instruments Information regarding changes in the fair value of the Company's derivative and non-derivative instruments is as follows: Gain (Loss) Recognized in Other Comprehensive Income (Loss) Gain (Loss) Recognized in Earnings (Loss) Three Months Ended September 30, Statement of Operations Classification 2023 2022 2023 2022 (In $ millions) Designated as Cash Flow Hedges Commodity swaps 5 (9) 1 11 Cost of sales Interest rate swaps — — (2) (1) Interest expense Foreign currency forwards — 2 4 — Cost of sales Total 5 (7) 3 10 Designated as Fair Value Hedges Cross-currency swaps (1) 18 — 40 — Foreign exchange gain (loss), net Designated as Net Investment Hedges Foreign currency denominated debt 61 148 — — N/A Cross-currency swaps 77 90 — — N/A Total 138 238 — — Not Designated as Hedges Foreign currency forwards and swaps — — (23) (8) Foreign exchange gain (loss), net; Other income (expense), net ______________________________ (1) In conjunction with the 2023 Offering ( Note 7 ) in August 2023, the Company entered into a cross-currency swap to effectively convert $500 million of the issued notes into a Japanese yen-denominated borrowing at prevailing yen interest rates, maturing on July 15, 2029. The swap qualifies and has been designated as a fair value hedge of the Company's foreign currency exchange rate exposure on the long-term debt of its Japanese yen-denominated subsidiary. Additionally, in conjunction with the 2023 Offering ( Note 7 ) in August 2023, the Company entered into cross-currency swaps to effectively convert $1.0 billion of the issued notes into 5-year and 7-year euro-denominated borrowings at prevailing euro interest rates, maturing on November 15, 2028 and November 15, 2030, respectively. The swaps qualify and have been designated as fair value hedges of the Company's foreign currency exchange rate exposure on the long-term debt of its euro-denominated subsidiary. Gain (Loss) Recognized in Other Comprehensive Income (Loss) Gain (Loss) Recognized in Earnings (Loss) Nine Months Ended September 30, Statement of Operations Classification 2023 2022 2023 2022 (In $ millions) Designated as Cash Flow Hedges Commodity swaps (2) 50 2 22 Cost of sales Interest rate swaps — — (6) (5) Interest expense Foreign currency forwards 4 2 2 — Cost of sales Total 2 52 (2) 17 Designated as Fair Value Hedges Cross-currency swaps 18 — 40 — Foreign exchange gain (loss), net Designated as Net Investment Hedges (1) Foreign currency denominated debt — 269 — — N/A Cross-currency swaps (16) 117 — — N/A Total (16) 386 — — Not Designated as Hedges Foreign currency forwards and swaps — — (22) (12) Foreign exchange gain (loss), net; Other income (expense), net ______________________________ (1) Concurrently with offering of the Acquisition USD Notes in July 2022 ( Note 7 ), the Company entered into cross-currency swaps to effectively convert $2.0 billion and $500 million of the Acquisition USD Notes into a euro-denominated borrowing at prevailing euro interest rates, maturing on July 15, 2027 and July 15, 2032, respectively. The swaps and €1.5 billion of the Acquisition Euro Notes qualify and have been designated as net investment hedges of the Company's foreign currency exchange rate exposure on the net investments of certain of its euro-denominated subsidiaries. See Note 13 for additional information regarding the fair value of the Company's derivative instruments. Certain of the Company's commodity swaps, interest rate swaps, cross-currency swaps and foreign currency forwards and swaps permit the Company to net settle all contracts with the counterparty through a single payment in an agreed upon currency in the event of default or early termination of the contract, similar to a master netting arrangement. Information regarding the gross amounts of the Company's derivative instruments and the amounts offset in the unaudited consolidated balance sheets is as follows: As of As of (In $ millions) Derivative Assets Gross amount recognized 187 169 Gross amount offset in the consolidated balance sheets — — Net amount presented in the consolidated balance sheets 187 169 Gross amount not offset in the consolidated balance sheets 44 16 Net amount 143 153 As of As of (In $ millions) Derivative Liabilities Gross amount recognized 226 189 Gross amount offset in the consolidated balance sheets — — Net amount presented in the consolidated balance sheets 226 189 Gross amount not offset in the consolidated balance sheets 44 16 Net amount 182 173

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company's financial assets and liabilities are measured at fair value on a recurring basis as follows: Derivative financial instruments include interest rate swaps, commodity swaps, cross-currency swaps and foreign currency forwards and swaps and are valued in the market using discounted cash flow techniques. These techniques incorporate Level 1 and Level 2 fair value measurement inputs such as interest rates and foreign currency exchange rates. These market inputs are utilized in the discounted cash flow calculation considering the instrument's term, notional amount, discount rate and credit risk. Significant inputs to the derivative valuation for interest rate swaps, commodity swaps, cross-currency swaps and foreign currency forwards and swaps are observable in the active markets and are classified as Level 2 in the fair value measurement hierarchy. Fair Value Measurement Significant Other Observable Inputs (Level 2) Other assets Other liabilities Notional Amount Current Noncurrent Current Noncurrent (In millions) (In $ millions) As of September 30, 2023 Derivatives Designated as Cash Flow Hedges Commodity swaps $ 63 6 36 — — Foreign currency forwards and swaps $ 27 2 — — — Designated as Fair Value Hedges (1) Cross-currency swaps $ 1,500 33 10 6 18 Derivatives Designated as Net Investment Hedges Cross-currency swaps € 5,367 91 — 29 152 Derivatives Not Designated as Hedges Foreign currency forwards and swaps $ 2,098 9 — 11 10 Total 141 46 46 180 As of December 31, 2022 Derivatives Designated as Cash Flow Hedges Commodity swaps $ 82 9 39 2 — Foreign currency forwards and swaps $ 49 — — — — Derivatives Designated as Net Investment Hedges Cross-currency swaps € 5,639 99 13 58 126 Derivatives Not Designated as Hedges Foreign currency forwards and swaps $ 1,265 9 — 3 — Total 117 52 63 126 ______________________________ (1) The Company has intercompany loans that are exposed to volatility in currency exchange rates. The Company utilizes cross-currency swaps to hedge these exposures ( Note 12 ). Carrying values and fair values of financial instruments that are not carried at fair value are as follows: Fair Value Measurement Carrying Significant Other Unobservable Total (In $ millions) As of September 30, 2023 Equity investments without readily determinable fair values 170 — — — Insurance contracts in nonqualified trusts 21 21 — 21 Long-term debt, including current installments of long-term debt 13,431 12,894 150 13,044 As of December 31, 2022 Equity investments without readily determinable fair values 170 — — — Insurance contracts in nonqualified trusts 22 23 — 23 Long-term debt, including current installments of long-term debt 13,953 13,247 172 13,419 In general, the equity investments included in the table above are not publicly traded and their fair values are not readily determinable. The Company believes the carrying values approximate fair value. Insurance contracts in nonqualified trusts consist of long-term fixed income securities, which are valued using independent vendor pricing models with observable inputs in the active market and therefore represent a Level 2 fair value measurement. The fair value of long-term debt is based on valuations from third-party banks and market quotations and is classified as Level 2 in the fair value measurement hierarchy. The fair value of obligations under finance leases, which are included in long-term debt in the unaudited consolidated balance sheets, is based on lease payments and discount rates, which are not observable in the market and therefore represents a Level 3 fair value measurement. As of September 30, 2023 and December 31, 2022, the fair values of cash and cash equivalents, receivables, marketable securities, trade payables, short-term borrowings and the current installments of long-term debt approximate carrying values due to the short-term nature of these instruments. These items have been excluded from the table with the exception of the current installments of long-term debt.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments Guarantees The Company has agreed to guarantee or indemnify third parties for environmental and other liabilities pursuant to a variety of agreements, including asset and business divestiture agreements, leases, settlement agreements and various agreements with affiliated companies. Although many of these obligations contain monetary and/or time limitations, others do not provide such limitations. The Company has accrued for all probable and reasonably estimable losses associated with all known matters or claims. These known obligations include the following: • Demerger Obligations In connection with the Hoechst demerger, the Company agreed to indemnify Hoechst, and its legal successors, for various liabilities under the demerger agreement, including for environmental liabilities associated with contamination arising either from environmental damage in general ("Category A") or under 19 divestiture agreements entered into by Hoechst prior to the demerger ("Category B") ( Note 9 ). The Company's obligation to indemnify Hoechst, and its legal successors, is capped under Category B at €250 million. If and to the extent the environmental damage should exceed €750 million in aggregate, the Company's obligation to indemnify Hoechst and its legal successors applies, but is then limited to 33.33% of the remediation cost without further limitations. Cumulative payments under the divestiture agreements as of September 30, 2023 are $110 million. Though the Company is significantly under its obligation cap under Category B, most of the divestiture agreements have become time barred and/or any notified environmental damage claims have been partially settled. The Company has also undertaken in the demerger agreement to indemnify Hoechst and its legal successors for (i) 33.33% of any and all Category A liabilities that result from Hoechst being held as the responsible party pursuant to public law or current or future environmental law or by third parties pursuant to private or public law related to contamination and (ii) liabilities that Hoechst is required to discharge, including tax liabilities, which are associated with businesses that were included in the demerger but were not demerged due to legal restrictions on the transfers of such items. These indemnities do not provide for any monetary or time limitations. The Company has not been requested by Hoechst to make any payments in connection with this indemnification. Accordingly, the Company has not made any payments to Hoechst and its legal successors. Based on the Company's evaluation of currently available information, including the lack of requests for indemnification, the Company cannot estimate the remaining demerger obligations, if any, in excess of amounts accrued. • Divestiture Obligations The Company and its predecessor companies agreed to indemnify third-party purchasers of former businesses and assets for various pre-closing conditions, as well as for breaches of representations, warranties and covenants. Such liabilities also include environmental liability, product liability, antitrust and other liabilities. These indemnifications and guarantees represent standard contractual terms associated with typical divestiture agreements and, other than environmental liabilities, the Company does not believe that they expose the Company to significant risk ( Note 9 ). The Company has divested numerous businesses, investments and facilities through agreements containing indemnifications or guarantees to the purchasers. Many of the obligations contain monetary and/or time limitations, which extend through 2037. The aggregate amount of outstanding indemnifications and guarantees provided for under these agreements is $116 million as of September 30, 2023. Other agreements do not provide for any monetary or time limitations. Based on the Company's evaluation of currently available information, including the number of requests for indemnification or other payment received by the Company, the Company cannot estimate the remaining divestiture obligations, if any, in excess of amounts accrued. Purchase Obligations In the normal course of business, the Company enters into various purchase commitments for goods and services. The Company maintains a number of "take-or-pay" contracts for purchases of raw materials, utilities and other services. Certain of the contracts contain a contract termination buy-out provision that allows for the Company to exit the contracts for amounts less than the remaining take-or-pay obligations. Additionally, the Company has other outstanding commitments representing maintenance and service agreements, energy and utility agreements, consulting contracts and software agreements. As of September 30, 2023, the Company had unconditional purchase obligations of $3.9 billion, of which $172 million will be paid in 2023, $635 million in 2024, $555 million in 2025, $436 million in 2026, $353 million in 2027 and the balance thereafter through 2042. Contingencies The Company is involved in legal and regulatory proceedings, lawsuits, claims and investigations incidental to the normal conduct of business, relating to such matters as product liability, land disputes, insurance coverage disputes, contracts, employment, antitrust or competition, intellectual property, personal injury and other actions in tort, workers' compensation, chemical exposure, asbestos exposure, taxes, trade compliance, acquisitions and divestitures, claims of current and legacy shareholders, past waste disposal practices and release of chemicals into the environment. The Company is actively defending those matters where the Company is named as a defendant and, based on the current facts, does not believe the outcomes from these matters would be material to the Company's results of operations, cash flows or financial position. As previously reported, in July 2020, the Company settled a European Commission competition law investigation involving certain of its subsidiaries and three other companies related to certain past ethylene purchases. Shell Chemicals Europe has filed a claim for damages with the District Court of Amsterdam against four companies, including Celanese, arising from those activities, and the first court hearing was held in late September 2023. The Company intends to vigorously defend itself against this claim. While it is possible that additional parties could assert demands or claims related to this matter, based on information

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment Information	Segment Information Engineered Acetyl Other Eliminations Consolidated (In $ millions) Three Months Ended September 30, 2023 Net sales 1,528 1,220 — (25) (1) 2,723 Other (charges) gains, net ( Note 18 ) (15) — (2) — (17) Operating profit (loss) 691 (2) 272 (121) — 842 Equity in net earnings (loss) of affiliates 8 1 3 — 12 Depreciation and amortization 111 55 7 — 173 Capital expenditures 51 44 24 — 119 (3) Three Months Ended September 30, 2022 Net sales 929 1,397 — (25) (1) 2,301 Other (charges) gains, net ( Note 18 ) (14) — (1) — (15) Operating profit (loss) 114 312 (118) — 308 Equity in net earnings (loss) of affiliates 69 1 3 — 73 Depreciation and amortization 43 53 4 — 100 Capital expenditures 34 74 15 — 123 (3) ______________________________ (1) Includes intersegment sales primarily related to the Acetyl Chain. (2) Includes a $508 million gain related to the formation of the Nutrinova joint venture included in Gain (loss) on disposition of businesses and assets, net in the unaudited interim consolidated statements of operations ( Note 3 ). (3) Includes a decrease in accrued capital expenditures of $12 million and $16 million for the three months ended September 30, 2023 and 2022, respectively. Engineered Acetyl Other Eliminations Consolidated (In $ millions) Nine Months Ended September 30, 2023 Net sales 4,743 3,703 — (75) (1) 8,371 Other (charges) gains, net ( Note 18 ) (44) (1) (5) — (50) Operating profit (loss) 961 (2) 845 (378) — 1,428 Equity in net earnings (loss) of affiliates 37 4 9 — 50 Depreciation and amortization 335 163 19 — 517 Capital expenditures 154 162 63 — 379 (3) As of September 30, 2023 Goodwill and intangible assets, net 10,518 417 — — 10,935 Total assets 17,478 5,528 2,532 — 25,538 Nine Months Ended September 30, 2022 Net sales 2,787 4,608 — (70) (1) 7,325 Other (charges) gains, net ( Note 18 ) (14) — (1) — (15) Operating profit (loss) 404 1,243 (325) — 1,322 Equity in net earnings (loss) of affiliates 171 8 10 — 189 Depreciation and amortization 134 161 14 — 309 Capital expenditures 99 231 39 — 369 (3) As of December 31, 2022 Goodwill and intangible assets, net 10,826 421 — — 11,247 Total assets 20,611 5,471 190 — 26,272 ______________________________ (1) Includes intersegment sales primarily related to the Acetyl Chain. (2) Includes a $508 million gain related to the formation of the Nutrinova joint venture included in Gain (loss) on disposition of businesses and assets, net in the unaudited interim consolidated statements of operations ( Note 3 ). (3) Includes a decrease in accrued capital expenditures of $61 million and $31 million for the nine months ended September 30, 2023 and 2022, respectively.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2023
Revenue Recognition and Deferred Revenue [Abstract]
Revenue Recognition	Revenue Recognition The Company has certain contracts that represent take-or-pay revenue arrangements in which the Company's performance obligations extend over multiple years. As of September 30, 2023, the Company had $1.1 billion of remaining performance obligations related to take-or-pay contracts. The Company expects to recognize approximately $156 million of its remaining performance obligations as Net sales in 2023, $418 million in 2024, $256 million in 2025 and the balance thereafter. Contract Balances Contract liabilities primarily relate to advances or deposits received from the Company's customers before revenue is recognized. These amounts are recorded as deferred revenue and are included in Current and Noncurrent Other liabilities in the unaudited consolidated balance sheets. The Company does not have any material contract assets as of September 30, 2023. Disaggregated Revenue In general, the Company's business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. The Company manages its Engineered Materials business segment through its project management pipeline, which is comprised of a broad range of projects which are solutions-based and are tailored to each customer's unique needs. Projects are identified and selected based on success rate and may involve a number of different polymers per project for use in multiple end-use applications. Therefore, the Company is agnostic toward products and end-use markets for the Engineered Materials business segment. The Company manages its Acetyl Chain business segment by leveraging its ability to sell chemicals externally to end-use markets or downstream to its acetate tow, intermediate chemistry, emulsion polymers, redispersible powders and ethylene vinyl acetate polymers businesses. Decisions to sell externally and geographically or downstream and along the Acetyl Chain are based on market demand, trade flows and maximizing the value of its chemicals. Therefore, the Company's strategic focus is on executing within this integrated chain model and less on driving product-specific revenue. Further disaggregation of Net sales by business segment and geographic destination is as follows: Three Months Ended Nine Months Ended 2023 2022 2023 2022 (In $ millions) Engineered Materials North America 449 292 1,399 865 Europe and Africa 462 355 1,541 1,112 Asia-Pacific 580 256 1,682 733 South America 37 26 121 77 Total 1,528 929 4,743 2,787 Acetyl Chain North America 366 461 1,092 1,337 Europe and Africa 395 461 1,292 1,598 Asia-Pacific 406 401 1,152 1,472 South America 28 49 92 131 Total (1) 1,195 1,372 3,628 4,538 ______________________________ (1) Excludes intersegment sales of $25 million and $25 million for the three months ended September 30, 2023 and 2022, respectively. Excludes intersegment sales of $75 million and $70 million for the nine months ended September 30, 2023 and 2022, respectively.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	Earnings (Loss) Per Share Three Months Ended Nine Months Ended 2023 2022 2023 2022 (In $ millions, except share data) Amounts attributable to Celanese Corporation Earnings (loss) from continuing operations 952 192 1,265 1,134 Earnings (loss) from discontinued operations (1) (1) (3) (7) Net earnings (loss) 951 191 1,262 1,127 Weighted average shares - basic 108,918,986 108,428,982 108,814,288 108,336,574 Incremental shares attributable to equity awards (1) 520,500 636,988 523,752 822,258 Weighted average shares - diluted 109,439,486 109,065,970 109,338,040 109,158,832 ______________________________ (1) Excludes options to purchase 219,963 and 0 shares of Common Stock for the three months ended September 30, 2023 and 2022, respectively, and options to purchase 190,651 and 0 shares of Common Stock for the nine months ended September 30, 2023 and 2022, respectively, as their effect would have been antidilutive. Excludes 0 and 181,027 equity award shares for the three months ended September 30, 2023 and 2022, respectively, and 42,998 and 149,272 equity award shares for the nine months ended September 30, 2023 and 2022, respectively, as their effect would have been antidilutive.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsOn October 31, 2023, the Company announced the planned closure of its Polyamide 66 and High-Performance Nylon polymerization units at its facility in Uentrop, Germany to optimize production costs across its global network. As a result of the planned closure, the Company expects to incur exit and shutdown costs, excluding employee termination costs, of approximately $110 million to $125 million, consisting primarily of accelerated depreciation on property, plant and equipment of approximately $75 million to $85 million and plant closure costs of approximately $35 million to $40 million. In addition, the Company expects to incur certain employee termination costs, which are subject to works council consultation. All costs resulting from the planned closure are expected to be incurred during 2024.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net earnings (loss) attributable to Celanese Corporation	$ 951	$ 191	$ 1,262	$ 1,127

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2023
Recent Accounting Pronouncements [Abstract]
Estimates and Assumptions	Estimates and Assumptions The preparation of unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of Net sales, expenses and allocated charges during the reporting period. Significant estimates pertain to impairments of goodwill, intangible assets and other long-lived assets, purchase price allocations, restructuring costs and other (charges) gains, net, income taxes, pension
New Accounting Pronouncements, Policy	There are no recent Accounting Standard Updates issued by the Financial Accounting Standards Board which are expected to materially impact the Company's financial position, operating results or financial disclosures.

Acquisitions, Dispositions an_2

Acquisitions, Dispositions and Plant Closures Plant Closures (Tables)	9 Months Ended
	Sep. 30, 2023
Plant Closures [Abstract]
Business Acquisition, Pro Forma Information	The unaudited consolidated pro forma results are as follows: Three Months Ended Nine Months Ended (In $ millions) Proforma Net sales 3,141 9,965 Proforma Earnings (loss) from continuing operations before tax 163 760

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventories	As of As of (In $ millions) Finished goods 1,573 1,820 Work-in-process 169 202 Raw materials and supplies 595 786 Total 2,337 2,808

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Engineered Acetyl Chain Total (In $ millions) As of December 31, 2022 6,775 367 7,142 Acquisitions ( Note 3 ) (24) — (24) Disposition (1) (80) — (80) Exchange rate changes (45) (2) (47) As of September 30, 2023 (2) 6,626 365 6,991 ______________________________ (1) Related to the formation of the Nutrinova joint venture ( Note 3 ). (2) There were no accumulated impairment losses as of September 30, 2023.
Schedule of Finite-Lived Intangible Assets	Finite-lived intangible assets are as follows: Licenses Customer- Developed Covenants Total (In $ millions) Gross Asset Value As of December 31, 2022 42 2,455 601 55 3,153 Disposition (1) — (58) — — (58) Exchange rate changes (2) (23) (10) — (35) As of September 30, 2023 40 2,374 591 55 3,060 Accumulated Amortization As of December 31, 2022 (39) (567) (50) (40) (696) Amortization — (93) (30) (1) (124) Disposition (1) — 58 — — 58 Exchange rate changes 2 10 — — 12 As of September 30, 2023 (37) (592) (80) (41) (750) Net book value 3 1,782 511 14 2,310 ______________________________ (1) Related to the formation of the Nutrinova joint venture ( Note 3 ).
Schedule of Indefinite-Lived Intangible Assets	Indefinite-lived intangible assets are as follows: Trademarks (In $ millions) As of December 31, 2022 1,648 Disposition (1) (14) Exchange rate changes — As of September 30, 2023 1,634 ______________________________ (1) Related to the formation of the Nutrinova joint venture ( Note 3 ).
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated amortization expense for the succeeding five fiscal years is as follows: (In $ millions) 2024 161 2025 161 2026 160 2027 160 2028 160

Current Other Liabilities (Tabl

Current Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Other Liabilities, Current [Abstract]
Schedule of Current Other Liabilities	As of As of (In $ millions) Benefit obligations ( Note 8 ) 25 25 Customer rebates 79 101 Derivatives ( Note 12 ) 46 63 Interest ( Note 7 ) 137 265 Legal ( Note 14 ) 25 21 Operating leases 88 83 Restructuring ( Note 18 ) 21 6 Salaries and benefits 149 151 Sales and use tax/foreign withholding tax payable 104 108 Investment in affiliates 91 79 Other (1) 162 299 Total 927 1,201 ____________________________ (1) Includes $27 million and $166 million payable to DuPont related to the M&M Acquisition and transition activities as of September 30, 2023 and December 31, 2022, respectively.

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Short-term Debt	As of As of (In $ millions) Short-Term Borrowings and Current Installments of Long-Term Debt - Third Party and Affiliates Current installments of long-term debt 1,061 506 Short-term borrowings, including amounts due to affiliates (1) 142 500 Revolving credit facilities (2) 205 300 Total 1,408 1,306 ______________________________ (1) The weighted average interest rate was 2.9% and 5.8% as of September 30, 2023 and December 31, 2022, respectively. (2) The weighted average interest rate was 3.4% and 5.8% as of September 30, 2023 and December 31, 2022, respectively.
Schedule of Long-term Debt	As of As of (In $ millions) Long-Term Debt Senior unsecured notes due 2023, interest rate of 1.125% — 480 Senior unsecured notes due 2024, interest rate of 3.500% 473 499 Senior unsecured notes due 2024, interest rate of 5.900% 527 2,000 Senior unsecured notes due 2025, interest rate of 1.250% 318 320 Senior unsecured notes due 2025, interest rate of 6.050% 1,000 1,750 Senior unsecured term loan due 2025 (1) — 750 Senior unsecured notes due 2026, interest rate of 1.400% 400 400 Senior unsecured notes due 2026, interest rate of 4.777% 1,060 1,067 Senior unsecured notes due 2027, interest rate of 2.125% 528 531 Senior unsecured notes due 2027, interest rate of 6.165% 2,000 2,000 Senior unsecured term loan due 2027 (1) 1,000 1,000 Senior unsecured notes due 2028, interest rate of 0.625% 529 533 Senior unsecured notes due 2028, interest rate of 6.350% 1,000 — Senior unsecured notes due 2029, interest rate of 5.337% 529 533 Senior unsecured notes due 2029, interest rate of 6.330% 750 750 Senior unsecured notes due 2030, interest rate of 6.550% 999 — Senior unsecured notes due 2032, interest rate of 6.379% 1,000 1,000 Senior unsecured notes due 2033, interest rate of 6.700% 1,000 — Pollution control and industrial revenue bonds due at various dates through 2030 (2) 163 164 Bank loans due at various dates through 2030 (3) 5 4 Obligations under finance leases due at various dates through 2054 150 172 Subtotal 13,431 13,953 Unamortized deferred financing costs (4) (79) (74) Current installments of long-term debt (1,061) (506) Total 12,291 13,373 ______________________________ (1) The interest rate was 6.930% and 5.934% as of September 30, 2023 and December 31, 2022, respectively. (2) Interest rates range from 4.05% and 5.00%. (3) The weighted average interest rate was 2.6% and 1.3% as of September 30, 2023 and December 31, 2022, respectively. (4) Related to the Company's long-term debt, excluding obligations under finance leases.
Schedule of Balances Available for Borrowing	The Company's debt balances and amounts available for borrowing under its senior unsecured revolving credit facilities are as follows: As of (In $ millions) U.S. Revolving Credit Facility Borrowings outstanding — Available for borrowing 1,750 China Revolving Credit Facility Borrowings outstanding 205 Available for borrowing 35
Schedule of Senior Unsecured Notes Offering	On August 24, 2023, Celanese U.S. completed a public offering registered under the Securities Act of senior unsecured notes as follows (collectively, the "2023 Offering"): Maturity Date Aggregate Principal Discount to Par Interest Rate (In $ millions) November 15, 2028 1,000 99.986% 6.350% November 15, 2030 999 99.950% 6.550% November 15, 2033 1,000 99.992% 6.700%
Schedule of Cash Tender Offer	On August 25, 2023, Celanese U.S. completed a cash tender offer for $2.25 billion in aggregate principal amount (the "Tender Offer") as follows: Maturity Date Aggregate Principal Amount Tendered Purchase price per $1,000 principal amount Total Tender Offer Consideration Accrued and Unpaid Interest (In $ millions) (In $ millions) June 30, 2024 1,473 $ 999.92 1,473 12 March 15, 2025 750 $ 1,002.85 752 20 April 30, 2024 27 $ 983.95 27 —

Benefit Obligations (Tables)

Benefit Obligations (Tables)	9 Months Ended
	Sep. 30, 2023
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Costs Recognized	The components of net periodic benefit cost are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Pension Post-retirement Pension Post-retirement Pension Post-retirement Pension Post-retirement (In $ millions) Service cost 2 — 3 1 8 — 10 1 Interest cost 32 1 17 — 98 2 50 1 Expected return on plan assets (32) — (42) — (98) — (125) — Total 2 1 (22) 1 8 2 (65) 2
Schedule of Company Commitments to Fund Benefit Obligations	Benefit obligation funding is as follows: As of Total Expected 2023 (In $ millions) Cash contributions to defined benefit pension plans 20 27 Benefit payments to nonqualified pension plans 15 18 Benefit payments to other postretirement benefit plans 2 4
Schedule of Defined Benefit Plans Disclosures	Pension and postretirement benefit plan balances recognized in the unaudited consolidated balance sheets consist of the following: As of September 30, 2023 As of December 31, 2022 Pension Post-retirement Pension Post-retirement (In $ millions) Noncurrent Other assets 167 — 160 — Current Other liabilities (21) (3) (21) (3) Benefit obligations (357) (35) (372) (35) Net amount recognized (211) (38) (233) (38)

Environmental (Tables)

Environmental (Tables)	9 Months Ended
	Sep. 30, 2023
Environmental Remediation Obligations [Abstract]
Schedule of Environmental Remediation Reserves	The components of environmental remediation liabilities are as follows: As of As of (In $ millions) Demerger obligations ( Note 14 ) 17 20 Divestiture obligations ( Note 14 ) 13 14 Active sites 19 21 U.S. Superfund sites 8 10 Other environmental remediation liabilities 2 2 Total 59 67

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Schedule of Treasury Stock	Total From Shares repurchased 69,324,429 Average purchase price per share $ 83.71 Shares repurchased (in $ millions) $ 5,803 Aggregate Board of Directors repurchase authorizations during the period (in $ millions) $ 6,866
Schedule of Components of Other Comprehensive Income (Loss), Net	Three Months Ended September 30, 2023 2022 Gross Income Net Gross Income Net (In $ millions) Foreign currency translation gain (loss) 34 (27) 7 3 (52) (49) Gain (loss) on derivative hedges (21) 4 (17) (15) 4 (11) Pension and postretirement benefits gain (loss) (1) — (1) — — — Total 12 (23) (11) (12) (48) (60) Nine Months Ended September 30, 2023 2022 Gross Income Net Gross Income Net (In $ millions) Foreign currency translation gain (loss) (184) 3 (181) (119) (82) (201) Gain (loss) on derivative hedges (18) 5 (13) 37 (7) 30 Pension and postretirement benefits gain (loss) (2) 1 (1) 2 — 2 Total (204) 9 (195) (80) (89) (169)
Schedule of Adjustments to Accumulated Other Comprehensive Income (Loss), Net	Adjustments to Accumulated other comprehensive income (loss), net, are as follows: Foreign Gain (Loss) on Derivative Hedges ( Note 12 ) Pension and Postretirement Benefits Gain (Loss) ( Note 8 ) Accumulated (In $ millions) As of December 31, 2022 (488) (22) (8) (518) Other comprehensive income (loss) before reclassifications (184) 20 (2) (166) Amounts reclassified from accumulated other comprehensive income (loss) — (38) — (38) Income tax (provision) benefit 3 5 1 9 As of September 30, 2023 (669) (35) (9) (713)

Other (Charges) Gains, Net (Tab

Other (Charges) Gains, Net (Tables)	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Other (Charges) Gains, Net	Three Months Ended Nine Months Ended 2023 2022 2023 2022 (In $ millions) Restructuring (1) (7) (3) (40) (3) Asset impairments (9) (12) (9) (12) Plant/office closures (1) — (1) — Total (17) (15) (50) (15) ______________________________ (1) Includes employee termination benefits primarily related to Company-wide business optimization projects during the three and nine months ended September 30, 2023.
Schedule of Restructuring Reserve by Type of Cost	The changes in the restructuring liabilities by business segment are as follows: Engineered Acetyl Other Total (In $ millions) Employee Termination Benefits As of December 31, 2022 4 1 1 6 Additions 34 1 5 40 Cash payments (20) (1) (4) (25) As of September 30, 2023 18 1 2 21

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Schedule of Effective Tax Rate	Three Months Ended Nine Months Ended 2023 2022 2023 2022 (In percentages) Effective income tax rate (33) 40 (20) 24

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Changes in Fair Value of Derivatives	Information regarding changes in the fair value of the Company's derivative and non-derivative instruments is as follows: Gain (Loss) Recognized in Other Comprehensive Income (Loss) Gain (Loss) Recognized in Earnings (Loss) Three Months Ended September 30, Statement of Operations Classification 2023 2022 2023 2022 (In $ millions) Designated as Cash Flow Hedges Commodity swaps 5 (9) 1 11 Cost of sales Interest rate swaps — — (2) (1) Interest expense Foreign currency forwards — 2 4 — Cost of sales Total 5 (7) 3 10 Designated as Fair Value Hedges Cross-currency swaps (1) 18 — 40 — Foreign exchange gain (loss), net Designated as Net Investment Hedges Foreign currency denominated debt 61 148 — — N/A Cross-currency swaps 77 90 — — N/A Total 138 238 — — Not Designated as Hedges Foreign currency forwards and swaps — — (23) (8) Foreign exchange gain (loss), net; Other income (expense), net ______________________________ (1) In conjunction with the 2023 Offering ( Note 7 ) in August 2023, the Company entered into a cross-currency swap to effectively convert $500 million of the issued notes into a Japanese yen-denominated borrowing at prevailing yen interest rates, maturing on July 15, 2029. The swap qualifies and has been designated as a fair value hedge of the Company's foreign currency exchange rate exposure on the long-term debt of its Japanese yen-denominated subsidiary. Additionally, in conjunction with the 2023 Offering ( Note 7 ) in August 2023, the Company entered into cross-currency swaps to effectively convert $1.0 billion of the issued notes into 5-year and 7-year euro-denominated borrowings at prevailing euro interest rates, maturing on November 15, 2028 and November 15, 2030, respectively. The swaps qualify and have been designated as fair value hedges of the Company's foreign currency exchange rate exposure on the long-term debt of its euro-denominated subsidiary. Gain (Loss) Recognized in Other Comprehensive Income (Loss) Gain (Loss) Recognized in Earnings (Loss) Nine Months Ended September 30, Statement of Operations Classification 2023 2022 2023 2022 (In $ millions) Designated as Cash Flow Hedges Commodity swaps (2) 50 2 22 Cost of sales Interest rate swaps — — (6) (5) Interest expense Foreign currency forwards 4 2 2 — Cost of sales Total 2 52 (2) 17 Designated as Fair Value Hedges Cross-currency swaps 18 — 40 — Foreign exchange gain (loss), net Designated as Net Investment Hedges (1) Foreign currency denominated debt — 269 — — N/A Cross-currency swaps (16) 117 — — N/A Total (16) 386 — — Not Designated as Hedges Foreign currency forwards and swaps — — (22) (12) Foreign exchange gain (loss), net; Other income (expense), net ______________________________ (1) Concurrently with offering of the Acquisition USD Notes in July 2022 ( Note 7 ), the Company entered into cross-currency swaps to effectively convert $2.0 billion and $500 million of the Acquisition USD Notes into a euro-denominated borrowing at prevailing euro interest rates, maturing on July 15, 2027 and July 15, 2032, respectively. The swaps and €1.5 billion of the Acquisition Euro Notes qualify and have been designated as net investment hedges of the Company's foreign currency exchange rate exposure on the net investments of certain of its euro-denominated subsidiaries.
Offsetting Assets	Information regarding the gross amounts of the Company's derivative instruments and the amounts offset in the unaudited consolidated balance sheets is as follows: As of As of (In $ millions) Derivative Assets Gross amount recognized 187 169 Gross amount offset in the consolidated balance sheets — — Net amount presented in the consolidated balance sheets 187 169 Gross amount not offset in the consolidated balance sheets 44 16 Net amount 143 153
Offsetting Liabilities	As of As of (In $ millions) Derivative Liabilities Gross amount recognized 226 189 Gross amount offset in the consolidated balance sheets — — Net amount presented in the consolidated balance sheets 226 189 Gross amount not offset in the consolidated balance sheets 44 16 Net amount 182 173

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The Company's financial assets and liabilities are measured at fair value on a recurring basis as follows: Derivative financial instruments include interest rate swaps, commodity swaps, cross-currency swaps and foreign currency forwards and swaps and are valued in the market using discounted cash flow techniques. These techniques incorporate Level 1 and Level 2 fair value measurement inputs such as interest rates and foreign currency exchange rates. These market inputs are utilized in the discounted cash flow calculation considering the instrument's term, notional amount, discount rate and credit risk. Significant inputs to the derivative valuation for interest rate swaps, commodity swaps, cross-currency swaps and foreign currency forwards and swaps are observable in the active markets and are classified as Level 2 in the fair value measurement hierarchy. Fair Value Measurement Significant Other Observable Inputs (Level 2) Other assets Other liabilities Notional Amount Current Noncurrent Current Noncurrent (In millions) (In $ millions) As of September 30, 2023 Derivatives Designated as Cash Flow Hedges Commodity swaps $ 63 6 36 — — Foreign currency forwards and swaps $ 27 2 — — — Designated as Fair Value Hedges (1) Cross-currency swaps $ 1,500 33 10 6 18 Derivatives Designated as Net Investment Hedges Cross-currency swaps € 5,367 91 — 29 152 Derivatives Not Designated as Hedges Foreign currency forwards and swaps $ 2,098 9 — 11 10 Total 141 46 46 180 As of December 31, 2022 Derivatives Designated as Cash Flow Hedges Commodity swaps $ 82 9 39 2 — Foreign currency forwards and swaps $ 49 — — — — Derivatives Designated as Net Investment Hedges Cross-currency swaps € 5,639 99 13 58 126 Derivatives Not Designated as Hedges Foreign currency forwards and swaps $ 1,265 9 — 3 — Total 117 52 63 126 ______________________________ (1) The Company has intercompany loans that are exposed to volatility in currency exchange rates. The Company utilizes cross-currency swaps to hedge these exposures ( Note 12 ).
Schedule of Carrying Values and Fair Values of Financial Instruments	Carrying values and fair values of financial instruments that are not carried at fair value are as follows: Fair Value Measurement Carrying Significant Other Unobservable Total (In $ millions) As of September 30, 2023 Equity investments without readily determinable fair values 170 — — — Insurance contracts in nonqualified trusts 21 21 — 21 Long-term debt, including current installments of long-term debt 13,431 12,894 150 13,044 As of December 31, 2022 Equity investments without readily determinable fair values 170 — — — Insurance contracts in nonqualified trusts 22 23 — 23 Long-term debt, including current installments of long-term debt 13,953 13,247 172 13,419

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of Business Segments	Engineered Acetyl Other Eliminations Consolidated (In $ millions) Three Months Ended September 30, 2023 Net sales 1,528 1,220 — (25) (1) 2,723 Other (charges) gains, net ( Note 18 ) (15) — (2) — (17) Operating profit (loss) 691 (2) 272 (121) — 842 Equity in net earnings (loss) of affiliates 8 1 3 — 12 Depreciation and amortization 111 55 7 — 173 Capital expenditures 51 44 24 — 119 (3) Three Months Ended September 30, 2022 Net sales 929 1,397 — (25) (1) 2,301 Other (charges) gains, net ( Note 18 ) (14) — (1) — (15) Operating profit (loss) 114 312 (118) — 308 Equity in net earnings (loss) of affiliates 69 1 3 — 73 Depreciation and amortization 43 53 4 — 100 Capital expenditures 34 74 15 — 123 (3) ______________________________ (1) Includes intersegment sales primarily related to the Acetyl Chain. (2) Includes a $508 million gain related to the formation of the Nutrinova joint venture included in Gain (loss) on disposition of businesses and assets, net in the unaudited interim consolidated statements of operations ( Note 3 ). (3) Includes a decrease in accrued capital expenditures of $12 million and $16 million for the three months ended September 30, 2023 and 2022, respectively. Engineered Acetyl Other Eliminations Consolidated (In $ millions) Nine Months Ended September 30, 2023 Net sales 4,743 3,703 — (75) (1) 8,371 Other (charges) gains, net ( Note 18 ) (44) (1) (5) — (50) Operating profit (loss) 961 (2) 845 (378) — 1,428 Equity in net earnings (loss) of affiliates 37 4 9 — 50 Depreciation and amortization 335 163 19 — 517 Capital expenditures 154 162 63 — 379 (3) As of September 30, 2023 Goodwill and intangible assets, net 10,518 417 — — 10,935 Total assets 17,478 5,528 2,532 — 25,538 Nine Months Ended September 30, 2022 Net sales 2,787 4,608 — (70) (1) 7,325 Other (charges) gains, net ( Note 18 ) (14) — (1) — (15) Operating profit (loss) 404 1,243 (325) — 1,322 Equity in net earnings (loss) of affiliates 171 8 10 — 189 Depreciation and amortization 134 161 14 — 309 Capital expenditures 99 231 39 — 369 (3) As of December 31, 2022 Goodwill and intangible assets, net 10,826 421 — — 11,247 Total assets 20,611 5,471 190 — 26,272 ______________________________ (1) Includes intersegment sales primarily related to the Acetyl Chain. (2) Includes a $508 million gain related to the formation of the Nutrinova joint venture included in Gain (loss) on disposition of businesses and assets, net in the unaudited interim consolidated statements of operations ( Note 3 ). (3) Includes a decrease in accrued capital expenditures of $61 million and $31 million for the nine months ended September 30, 2023 and 2022, respectively.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue Recognition and Deferred Revenue [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	Further disaggregation of Net sales by business segment and geographic destination is as follows: Three Months Ended Nine Months Ended 2023 2022 2023 2022 (In $ millions) Engineered Materials North America 449 292 1,399 865 Europe and Africa 462 355 1,541 1,112 Asia-Pacific 580 256 1,682 733 South America 37 26 121 77 Total 1,528 929 4,743 2,787 Acetyl Chain North America 366 461 1,092 1,337 Europe and Africa 395 461 1,292 1,598 Asia-Pacific 406 401 1,152 1,472 South America 28 49 92 131 Total (1) 1,195 1,372 3,628 4,538 ______________________________ (1) Excludes intersegment sales of $25 million and $25 million for the three months ended September 30, 2023 and 2022, respectively. Excludes intersegment sales of $75 million and $70 million for the nine months ended September 30, 2023 and 2022, respectively.

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Earnings (Loss) Per Share	Three Months Ended Nine Months Ended 2023 2022 2023 2022 (In $ millions, except share data) Amounts attributable to Celanese Corporation Earnings (loss) from continuing operations 952 192 1,265 1,134 Earnings (loss) from discontinued operations (1) (1) (3) (7) Net earnings (loss) 951 191 1,262 1,127 Weighted average shares - basic 108,918,986 108,428,982 108,814,288 108,336,574 Incremental shares attributable to equity awards (1) 520,500 636,988 523,752 822,258 Weighted average shares - diluted 109,439,486 109,065,970 109,338,040 109,158,832 ______________________________ (1) Excludes options to purchase 219,963 and 0 shares of Common Stock for the three months ended September 30, 2023 and 2022, respectively, and options to purchase 190,651 and 0 shares of Common Stock for the nine months ended September 30, 2023 and 2022, respectively, as their effect would have been antidilutive. Excludes 0 and 181,027 equity award shares for the three months ended September 30, 2023 and 2022, respectively, and 42,998 and 149,272 equity award shares for the nine months ended September 30, 2023 and 2022, respectively, as their effect would have been antidilutive.

Description of the Company an_2

Description of the Company and Basis of Presentation (Narrative) (Details)	Sep. 30, 2023
Consolidated Ventures
Variable Interest Entity [Line Items]
Noncontrolling interest, ownership percentage by parent	100%

Acquisitions, Dispositions an_3

Acquisitions, Dispositions and Plant Closures Plant Closures - Narrative (Details) € in Millions, $ in Millions					3 Months Ended		9 Months Ended
	Sep. 27, 2023 USD ($)	Nov. 01, 2022 USD ($) employees facility patent	Apr. 01, 2022 USD ($) annualInstallment	Apr. 01, 2022 EUR (€) annualInstallment	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Restructuring Cost and Reserve [Line Items]
Gain (Loss) on Disposition of Assets					$ 503	$ (2)	$ 508	$ 7
Proceeds from sale of businesses and assets, net							$ 480	16
Nutrinova Joint Venture
Restructuring Cost and Reserve [Line Items]
Gain (Loss) on Disposition of Assets	$ 508
Korea Engineering Plastics Co., Ltd.
Restructuring Cost and Reserve [Line Items]
Payments to equity method investment			$ 5	€ 24
Number of equal annual investments restructuring payment | annualInstallment			5	5
Equity method investment, increase			$ 134
Celanese Corporation | Nutrinova Joint Venture
Restructuring Cost and Reserve [Line Items]
Equity method investment, ownership percentage	30%
Celanese Corporation | Korea Engineering Plastics Co., Ltd.
Restructuring Cost and Reserve [Line Items]
Equity method investment, ownership percentage			50%	50%
Mitsui & Co. Ltd. | Nutrinova Joint Venture
Restructuring Cost and Reserve [Line Items]
Equity method investment, ownership percentage	70%
Proceeds from sale of businesses and assets, net	$ 503
Mitsubishi Gas Chemical Company | Korea Engineering Plastics Co., Ltd.
Restructuring Cost and Reserve [Line Items]
Equity method investment, ownership percentage			50%	50%
Mobility & Materials
Restructuring Cost and Reserve [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired		100%
Payments to acquire businesses, gross		$ 11,000
Number of facilities | facility		29
Number of patents | patent		850
Entity number of employees | employees		5,000
Business Combination, Pro Forma Information, Interest Expense and Debt Issuance Cost Amortization						57		400
Business Combination, Pro Forma Information, Inventory Step Up Amortization						$ 0		$ 131

Acquisitions, Dispositions an_4

Acquisitions, Dispositions and Plant Closures - Business Acquisition, Pro Forma Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Proforma Net sales	$ 3,141	$ 9,965
Proforma Earnings (loss) from continuing operations before tax	$ 163	$ 760

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods	$ 1,573	$ 1,820
Work-in-process	169	202
Raw materials and supplies	595	786
Total	$ 2,337	$ 2,808

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($)
Goodwill [Line Items]
As of December 31, 2022	$ 7,142
Acquisitions (Note 3)	(24)
Goodwill, Transfers	(80)	[1]
Exchange rate changes	(47)
As of September 30, 2023(2)	6,991	[2]
Goodwill, impaired, accumulated impairment loss	0
Goodwill, impairment loss	0
Engineered Materials
Goodwill [Line Items]
As of December 31, 2022	6,775
Acquisitions (Note 3)	(24)
Goodwill, Transfers	(80)	[1]
Exchange rate changes	(45)
As of September 30, 2023(2)	6,626	[2]
Acetyl Chain
Goodwill [Line Items]
As of December 31, 2022	367
Acquisitions (Note 3)	0
Goodwill, Transfers	0	[1]
Exchange rate changes	(2)
As of September 30, 2023(2)	$ 365	[2]
[1] Related to the formation of the Nutrinova joint venture ( Note 3 ).

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Finite-Lived Intangible Assets [Line Items]
As of December 31, 2022				$ 3,153
Disposition(1)	[1]			58
Exchange rate changes				(35)
As of September 30, 2023		$ 3,060		3,060
As of December 31, 2022				(696)
Amortization		(41)	$ (10)	(124)	$ (32)
Finite-Lived Intangible Assets, Transferred, Accumulated Amortization	[1]			(58)
Exchange rate changes				12
As of September 30, 2023		(750)		(750)
Net book value		2,310		2,310
Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend				0
Licenses
Finite-Lived Intangible Assets [Line Items]
As of December 31, 2022				42
Disposition(1)	[1]			0
Exchange rate changes				(2)
As of September 30, 2023		40		40
As of December 31, 2022				(39)
Amortization				0
Finite-Lived Intangible Assets, Transferred, Accumulated Amortization	[1]			0
Exchange rate changes				2
As of September 30, 2023		(37)		(37)
Net book value		3		3
Customer- Related Intangible Assets
Finite-Lived Intangible Assets [Line Items]
As of December 31, 2022				2,455
Disposition(1)	[1]			58
Exchange rate changes				(23)
As of September 30, 2023		2,374		2,374
As of December 31, 2022				(567)
Amortization				(93)
Finite-Lived Intangible Assets, Transferred, Accumulated Amortization	[1]			(58)
Exchange rate changes				10
As of September 30, 2023		(592)		(592)
Net book value		1,782		1,782
Developed Technology
Finite-Lived Intangible Assets [Line Items]
As of December 31, 2022				601
Disposition(1)	[1]			0
Exchange rate changes				(10)
As of September 30, 2023		591		591
As of December 31, 2022				(50)
Amortization				(30)
Finite-Lived Intangible Assets, Transferred, Accumulated Amortization	[1]			0
Exchange rate changes				0
As of September 30, 2023		(80)		(80)
Net book value		511		511
Covenants Not to Compete and Other
Finite-Lived Intangible Assets [Line Items]
As of December 31, 2022				55
Disposition(1)	[1]			0
Exchange rate changes				0
As of September 30, 2023		55		55
As of December 31, 2022				(40)
Amortization				(1)
Finite-Lived Intangible Assets, Transferred, Accumulated Amortization	[1]			0
Exchange rate changes				0
As of September 30, 2023		(41)		(41)
Net book value		$ 14		$ 14
[1] Related to the formation of the Nutrinova joint venture ( Note 3 ).

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Schedule of Indefinite-Lived Intangible Assets (Details) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($)
Indefinite-lived Intangible Assets [Line Items]
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)	$ 0
Trademarks and Trade Names
Indefinite-lived Intangible Assets [Line Items]
As of December 31, 2022	1,648
Disposition(1)	(14)	[1]
Exchange rate changes	0
As of September 30, 2023	$ 1,634
[1] Related to the formation of the Nutrinova joint venture ( Note 3 ).

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets, Net - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) $ in Millions	Sep. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 161
2025	161
2026	160
2027	160
2028	$ 160

Current Other Liabilities (Deta

Current Other Liabilities (Details) - USD ($) $ in Millions		Sep. 30, 2023	Dec. 31, 2022
Current Other Liabilities [Line Items]
Benefit obligations (Note 8)		$ 25	$ 25
Customer rebates		79	101
Derivatives (Note 12)		46	63
Interest (Note 7)		137	265
Legal (Note 14)		25	21
Operating leases		88	83
Restructuring (Note 18)		21	6
Salaries and benefits		149	151
Sales and use tax/foreign withholding tax payable		104	108
Investment in affiliates		91	79
Other Sundry Liabilities, Current	[1]	162	299
Total		927	1,201
Mobility & Materials
Current Other Liabilities [Line Items]
Other Sundry Liabilities, Current		$ 27	$ 166
[1]Includes $27 million and $166 million payable to DuPont related to the M&M Acquisition and transition activities as of September 30, 2023 and December 31, 2022, respectively.

Debt - Schedule of Short-term D

Debt - Schedule of Short-term Debt (Details) - USD ($) $ in Millions		Sep. 30, 2023	Dec. 31, 2022
Short-Term Borrowings and Current Installments of Long-Term Debt - Third Party and Affiliates
Current installments of long-term debt		$ 1,061	$ 506
Short-term borrowings, including amounts due to affiliates(1)	[1]	142	500
Total		$ 1,408	$ 1,306
Loans Payable
Short-Term Borrowings and Current Installments of Long-Term Debt - Third Party and Affiliates
Weighted average interest rate, short-term borrowings		2.90%	5.80%
Revolving Credit Facility
Short-Term Borrowings and Current Installments of Long-Term Debt - Third Party and Affiliates
Weighted average interest rate, short-term borrowings		3.40%	5.80%
Revolving Credit Facility
Short-Term Borrowings and Current Installments of Long-Term Debt - Third Party and Affiliates
Revolving credit facilities(2)	[2]	$ 205	$ 300
Revolving Credit Facility | Revolving Credit Facility
Short-Term Borrowings and Current Installments of Long-Term Debt - Third Party and Affiliates
Revolving credit facilities(2)		$ 0
[1]The weighted average interest rate was 2.9% and 5.8% as of September 30, 2023 and December 31, 2022, respectively.[2]The weighted average interest rate was 3.4% and 5.8% as of September 30, 2023 and December 31, 2022, respectively.

Debt - Schedule of Long-term De

Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Millions		Sep. 30, 2023	Aug. 24, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total debt		$ 150		$ 172
Subtotal		13,431		13,953
Unamortized debt issuance costs	[1]	(79)		(74)
Long-Term Debt and Lease Obligation, Current		(1,061)		(506)
Total		12,291		13,373
Senior Unsecured Notes Due 2023
Debt Instrument [Line Items]
Senior unsecured debt		$ 0		480
Debt Instrument, Interest Rate, Stated Percentage		1.125%
Senior Unsecured Notes Due 2024
Debt Instrument [Line Items]
Senior unsecured debt		$ 473		499
Debt Instrument, Interest Rate, Stated Percentage		3.50%
Acquisition Notes Due July 2024
Debt Instrument [Line Items]
Senior unsecured debt		$ 527		2,000
Debt Instrument, Interest Rate, Stated Percentage		5.90%
Senior Unsecured Notes Due 2025
Debt Instrument [Line Items]
Senior unsecured debt		$ 318		320
Debt Instrument, Interest Rate, Stated Percentage		1.25%
Acquisition Notes Due March 2025
Debt Instrument [Line Items]
Senior unsecured debt		$ 1,000		1,750
Debt Instrument, Interest Rate, Stated Percentage		6.05%
Senior Unsecured Term Loan Due 2025
Debt Instrument [Line Items]
Senior unsecured debt	[2]	$ 0		$ 750
Debt Instrument, Interest Rate, Stated Percentage				5.934%
Senior Unsecured Notes Due 2026
Debt Instrument [Line Items]
Senior unsecured debt		$ 400		$ 400
Debt Instrument, Interest Rate, Stated Percentage		1.40%
EUR Senior Unsecured Notes Due 2026
Debt Instrument [Line Items]
Senior unsecured debt		$ 1,060		1,067
Debt Instrument, Interest Rate, Stated Percentage		4.777%
Senior Unsecured Notes Due 2027
Debt Instrument [Line Items]
Senior unsecured debt		$ 528		531
Debt Instrument, Interest Rate, Stated Percentage		2.125%
USD Senior Unsecured Notes Due 2027
Debt Instrument [Line Items]
Senior unsecured debt		$ 2,000		2,000
Debt Instrument, Interest Rate, Stated Percentage		6.165%
Senior Unsecured Term Loan Due 2027
Debt Instrument [Line Items]
Senior unsecured debt	[2]	$ 1,000		$ 1,000
Debt Instrument, Interest Rate, Stated Percentage		6.93%		5.934%
Senior Unsecured Notes Due 2028
Debt Instrument [Line Items]
Senior unsecured debt		$ 529		$ 533
Debt Instrument, Interest Rate, Stated Percentage		0.625%
EUR Senior Unsecured Notes Due 2029
Debt Instrument [Line Items]
Senior unsecured debt		$ 529		533
Debt Instrument, Interest Rate, Stated Percentage		5.337%
Acquisition Notes Due July 2029
Debt Instrument [Line Items]
Senior unsecured debt		$ 750		750
Debt Instrument, Interest Rate, Stated Percentage		6.33%
USD Senior Unsecured Notes Due 2032
Debt Instrument [Line Items]
Senior unsecured debt		$ 1,000		1,000
Debt Instrument, Interest Rate, Stated Percentage		6.379%
Refunding loan for pollution control and industrial revenue bonds
Debt Instrument [Line Items]
Other long-term debt	[3]	$ 163		164
Refunding loan for pollution control and industrial revenue bonds | Minimum
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		4.05%
Refunding loan for pollution control and industrial revenue bonds | Maximum
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		5%
Loans Payable
Debt Instrument [Line Items]
Other long-term debt	[4]	$ 5		$ 4
Long-term debt, weighted average interest rate, at point in time		2.60%		1.30%
USD Senior Unsecured Notes Due 2028
Debt Instrument [Line Items]
Senior unsecured debt		$ 1,000		$ 0
Debt Instrument, Interest Rate, Stated Percentage		6.35%	6.35%
USD Senior Unsecured Notes Due 2030
Debt Instrument [Line Items]
Senior unsecured debt		$ 999		0
Debt Instrument, Interest Rate, Stated Percentage		6.55%	6.55%
USD Senior Unsecured Notes Due 2033
Debt Instrument [Line Items]
Senior unsecured debt		$ 1,000		$ 0
Debt Instrument, Interest Rate, Stated Percentage		6.70%	6.70%
[1]Related to the Company's long-term debt, excluding obligations under finance leases.[2]The interest rate was 6.930% and 5.934% as of September 30, 2023 and December 31, 2022, respectively.[3]Interest rates range from 4.05% and 5.00%.[4]The weighted average interest rate was 2.6% and 1.3% as of September 30, 2023 and December 31, 2022, respectively.

Debt - Senior Credit Facilities

Debt - Senior Credit Facilities Narrative (Details) ¥ in Millions, $ in Millions	Jan. 06, 2023 CNY (¥)	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jan. 04, 2023 CNY (¥)
364 Day Delayed-Draw Term Loan | Term Loan Facility
Debt Instrument [Line Items]
Debt instrument, term			364 days
Debt instrument, face amount			$ 500
5 Year Delayed-Draw Term Loan | Term Loan Facility
Debt Instrument [Line Items]
Debt instrument, term			5 years
Debt instrument, face amount			$ 1,000
3 Year Delayed-Draw Term Loan | Term Loan Facility
Debt Instrument [Line Items]
Debt instrument, term		3 years
Debt instrument, face amount		$ 750
Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing base			$ 1,750
China Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing base | ¥				¥ 1,750
China Working Capital Term Loan | China Working Capital Term Loan
Debt Instrument [Line Items]
Debt instrument, term	12 months
Debt instrument, face amount | ¥	¥ 800
China Working Capital Term Loan | China Working Capital Term Loan | Variable Interbank Interest Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.50%

Debt - Schedule of Revolving Cr

Debt - Schedule of Revolving Credit Facility (Details) - Revolving Credit Facility - USD ($) $ in Millions		Sep. 30, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Revolving credit facilities(2)	[1]	$ 205	$ 300
Revolving Credit Facility
Line of Credit Facility [Line Items]
Revolving credit facilities(2)		0
Available for borrowing		1,750
China Revolving Credit Facility
Line of Credit Facility [Line Items]
Revolving credit facilities(2)		205
Available for borrowing		$ 35
[1]The weighted average interest rate was 3.4% and 5.8% as of September 30, 2023 and December 31, 2022, respectively.

Debt - Senior Notes Narrative (

Debt - Senior Notes Narrative (Details) € in Billions			3 Months Ended		9 Months Ended
	Aug. 25, 2023 USD ($)	Jul. 31, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Aug. 24, 2023 USD ($)	Jul. 31, 2022 EUR (€)
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage					100%
Debt Instrument, Repurchased Face Amount	$ 2,250,000,000
Refinancing expense	7,000,000		$ 7,000,000	$ 0	$ 7,000,000	$ 0
Acquisition Notes
Debt Instrument [Line Items]
Debt instrument, face amount		$ 7,500,000,000						€ 1.5
Notes offering related costs		$ 65,000,000
Acquisition Notes Due July 2024
Debt Instrument [Line Items]
Debt Instrument, Repurchased Face Amount	1,473,000,000
Debt Instrument Tender Purchase Price Per 1000 Principal Amount	999.92
Debt Instrument, Repurchase Amount	1,473,000,000
Interest Expense, Debt	12,000,000
Debt Instrument, Interest Rate, Stated Percentage			5.90%		5.90%
Acquisition Notes Due March 2025
Debt Instrument [Line Items]
Debt Instrument, Repurchased Face Amount	750,000,000
Debt Instrument Tender Purchase Price Per 1000 Principal Amount	1,002.85
Debt Instrument, Repurchase Amount	752,000,000
Interest Expense, Debt	20,000,000
Debt Instrument, Interest Rate, Stated Percentage			6.05%		6.05%
Senior Unsecured Notes Due 2024
Debt Instrument [Line Items]
Debt Instrument, Repurchased Face Amount	27,000,000
Debt Instrument Tender Purchase Price Per 1000 Principal Amount	983.95
Debt Instrument, Repurchase Amount	27,000,000
Interest Expense, Debt	$ 0
Debt Instrument, Interest Rate, Stated Percentage			3.50%		3.50%
USD Senior Unsecured Notes Due 2028
Debt Instrument [Line Items]
Debt instrument, face amount							$ 1,000,000,000
Debt Instrument, Interest Rate, Stated Percentage			6.35%		6.35%		6.35%
Debt Instrument, Discount Price, Percentage							99.986%
USD Senior Unsecured Notes Due 2030
Debt Instrument [Line Items]
Debt instrument, face amount							$ 999,000,000
Debt Instrument, Interest Rate, Stated Percentage			6.55%		6.55%		6.55%
Debt Instrument, Discount Price, Percentage							99.95%
USD Senior Unsecured Notes Due 2033
Debt Instrument [Line Items]
Debt instrument, face amount							$ 1,000,000,000
Debt Instrument, Interest Rate, Stated Percentage			6.70%		6.70%		6.70%
Debt Instrument, Discount Price, Percentage							99.992%
2023 Offering of Senior Unsecured Notes
Debt Instrument [Line Items]
Debt Issuance Costs, Gross							$ 26,000,000

Debt - Accounts Receivable Secu

Debt - Accounts Receivable Securitization Facility Narrative (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Amended restated receivable securitization facility | Secured Debt
Line of Credit Facility [Line Items]
Percentage of fair value of sales receivables	100%
Secured Debt | Amended restated receivable securitization facility
Line of Credit Facility [Line Items]
Transfer of financial assets accounted for as sales, amount derecognized	$ 1,000	$ 1,100
Proceeds collected on accounts receivable sold under factoring facilities	977	$ 1,100
Cash flows between transferor and transferee, proceeds from new transfers	$ 110

Debt - Factoring and Discountin

Debt - Factoring and Discounting Agreements Narrative (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Europe Factoring Agreements
Debt Instrument [Line Items]
Transfer of financial assets accounted for as sales, non-recourse basis, account receivable percentage	100%
Singapore Factoring Agreements
Debt Instrument [Line Items]
Transfer of financial assets accounted for as sales, non-recourse basis, account receivable percentage	90%
Europe and Singapore Factoring Agreement
Debt Instrument [Line Items]
Transfer of financial assets accounted for as sales, amount derecognized	$ 305	$ 320
Proceeds collected on accounts receivable sold under factoring facilities	$ 294	$ 325

Benefit Obligations - Schedule

Benefit Obligations - Schedule of Net Periodic Benefit Costs Recognized (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 2	$ 3	$ 8	$ 10
Interest cost	32	17	98	50
Expected return on plan assets	(32)	(42)	(98)	(125)
Total	2	(22)	8	(65)
Post-retirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	1	0	1
Interest cost	1	0	2	1
Expected return on plan assets	0	0	0	0
Total	$ 1	$ 1	$ 2	$ 2

Benefit Obligations - Schedul_2

Benefit Obligations - Schedule of Company Commitments to Fund Benefit Obligations (Details) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($)
Cash contributions to defined benefit pension plans
Defined Benefit Plan Disclosure [Line Items]
Total contributions year-to-date	$ 20
Total expected contributions in current fiscal year	27
Benefit payments to nonqualified pension plans
Defined Benefit Plan Disclosure [Line Items]
Total contributions year-to-date	15
Total expected contributions in current fiscal year	18
Benefit payments to other postretirement benefit plans
Defined Benefit Plan Disclosure [Line Items]
Total contributions year-to-date	2
Total expected contributions in current fiscal year	$ 4

Benefit Obligations - Schedul_3

Benefit Obligations - Schedule of Defined Benefit Plans Disclosures (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Noncurrent Other assets	$ 167	$ 160
Current Other liabilities	(21)	(21)
Benefit obligations	(357)	(372)
Net amount recognized	(211)	(233)
Post-retirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Noncurrent Other assets	0	0
Current Other liabilities	(3)	(3)
Benefit obligations	(35)	(35)
Net amount recognized	$ (38)	$ (38)

Environmental (Schedule of Envi

Environmental (Schedule of Environmental Remediation Reserves) (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Environmental Remediation Obligations [Abstract]
Demerger obligations (Note 14)	$ 17	$ 20
Divestiture obligations (Note 14)	13	14
Active sites	19	21
U.S. Superfund sites	8	10
Other environmental remediation liabilities	2	2
Total	$ 59	$ 67

Environmental - US Superfund Si

Environmental - US Superfund Sites Narrative (Details) - Passaic River, New Jersey $ in Millions					9 Months Ended
	Mar. 24, 2023 USD ($)	Dec. 16, 2022 USD ($)	Sep. 30, 2021 USD ($)	Mar. 31, 2016 USD ($)	Sep. 30, 2023
Site Contingency [Line Items]
Number of parties included in USEPA order	40				70
Cost of EPA's plan estimate	$ 71	$ 150	$ 441	$ 1,400
Environmental liability percentage					1%

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Oct. 18, 2023	Sep. 30, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Common stock, par value (in dollars per share)		$ 0.0001	$ 0.0001
Subsequent Event
Class of Stock [Line Items]
Common stock, dividends, declared (in dollar per share)	$ 0.70
Dividends, common stock, cash	$ 76

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Treasury Stock (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended		188 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Shares repurchased (in shares)	0	0	69,324,429
Average purchase price (in dollar per share)			$ 83.71
Shares repurchased (in $ millions)			$ 5,803
Aggregate Board of Directors repurchase authorizations during the period (in $ millions)			$ 6,866

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Components of Other Comprehensive Income (Loss), Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Foreign currency translation gain (loss), gross amount	$ 34	$ 3	$ (184)	$ (119)
Foreign currency translation gain (loss), income tax (provision) benefit	(27)	(52)	3	(82)
Foreign currency translation gain (loss)	7	(49)	(181)	(201)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax	(17)	(11)	(13)	30
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments, Tax	(4)	(4)	(5)	7
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments, before Tax	(21)	(15)	(18)	37
Total other comprehensive income (loss), before tax	12	(12)	(204)	(80)
Total other comprehensive income (loss), tax	23	48	(9)	89
Total other comprehensive income (loss), net of tax	(11)	(60)	(195)	(169)
Pension and postretirement benefits gain (loss), gross amount	(1)	0	(2)	2
Pension and postretirement benefits gain (loss), income tax (provision) benefit	0	0	1	0
Pension and postretirement benefits	$ (1)	$ 0	$ (1)	$ 2

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Adjustments to Accumulated Other Comprehensive Income (Loss), Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss), net [Line Items]
As of December 31, 2022			$ (518)
Other comprehensive income (loss) before reclassifications			(166)
Amounts reclassified from accumulated other comprehensive income (loss)			(38)
Income tax (provision) benefit	$ (23)	$ (48)	9	$ (89)
As of September 30, 2023	(713)		(713)
Foreign Currency Translation Gain (Loss)
Accumulated Other Comprehensive Income (Loss), net [Line Items]
As of December 31, 2022			(488)
Other comprehensive income (loss) before reclassifications			(184)
Amounts reclassified from accumulated other comprehensive income (loss)			0
Income tax (provision) benefit			3
As of September 30, 2023	(669)		(669)
Gain (Loss) on Derivative Hedges (Note 12)
Accumulated Other Comprehensive Income (Loss), net [Line Items]
As of December 31, 2022			(22)
Other comprehensive income (loss) before reclassifications			20
Amounts reclassified from accumulated other comprehensive income (loss)			(38)
Income tax (provision) benefit			5
As of September 30, 2023	(35)		(35)
Pension and Postretirement Benefits Gain (Loss) (Note 8)
Accumulated Other Comprehensive Income (Loss), net [Line Items]
As of December 31, 2022			(8)
Other comprehensive income (loss) before reclassifications			(2)
Amounts reclassified from accumulated other comprehensive income (loss)			0
Income tax (provision) benefit			1
As of September 30, 2023	$ (9)		$ (9)

Other (Charges) Gains, Net - Sc

Other (Charges) Gains, Net - Schedule of Other (Charges) Gains, Net (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2023		Sep. 30, 2022	Sep. 30, 2023		Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Restructuring(1)	$ (7)	[1]	$ (3)	$ (40)	[1]	$ (3)
Asset impairments	(9)		(12)	(9)		(12)
Plant/office closures	(1)		0	(1)		0
Total	$ (17)		$ (15)	$ (50)		$ (15)
[1]Includes employee termination benefits primarily related to Company-wide business optimization projects during the three and nine months ended September 30, 2023.

Other (Charges) Gains, Net - _2

Other (Charges) Gains, Net - Schedule of Restructuring Reserve by Type of Cost (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2023		Sep. 30, 2022	Sep. 30, 2023		Sep. 30, 2022
Restructuring Reserve [Roll Forward]
Additions	$ 7	[1]	$ 3	$ 40	[1]	$ 3
Employee Severance
Restructuring Reserve [Roll Forward]
Beginning balance				6
Additions				40
Cash payments				(25)
Ending balance	21			21
Employee Severance | Engineered Materials
Restructuring Reserve [Roll Forward]
Beginning balance				4
Additions				34
Cash payments				(20)
Ending balance	18			18
Employee Severance | Acetyl Chain [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				1
Additions				1
Cash payments				(1)
Ending balance	1			1
Employee Severance | Other Activities
Restructuring Reserve [Roll Forward]
Beginning balance				1
Additions				5
Cash payments				(4)
Ending balance	$ 2			$ 2
[1]Includes employee termination benefits primarily related to Company-wide business optimization projects during the three and nine months ended September 30, 2023.

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Tax Rate (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Effective income tax rate	(33.00%)	40%	(20.00%)	24%

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	$ 293	$ 293

Derivative Financial Instrume_3

Derivative Financial Instruments (Schedule of Changes in Fair Value of Derivatives) (Details) € in Millions, $ in Millions						1 Months Ended	3 Months Ended				9 Months Ended
		Sep. 30, 2023 USD ($)	Sep. 30, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Jul. 31, 2022 EUR (€)	Aug. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)		Sep. 30, 2022 USD ($)		Sep. 30, 2023 USD ($)		Sep. 30, 2022 USD ($)		Dec. 31, 2022 USD ($)	Jul. 31, 2022 USD ($)
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument
Derivative [Line Items]
Gain (Loss) Recognized in Other Comprehensive Income (Loss)							$ 0		$ 0		$ 0		$ 0
Gain (Loss) Recognized in Earnings (Loss)							$ (23)		$ (8)		$ (22)		$ (12)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]							Foreign exchange gain (loss), net, Other income (expense), net		Foreign exchange gain (loss), net, Other income (expense), net		Foreign exchange gain (loss), net, Other income (expense), net		Foreign exchange gain (loss), net, Other income (expense), net
Derivative, notional amount		$ 2,098					$ 2,098				$ 2,098				$ 1,265
Cash Flow Hedging
Derivative [Line Items]
Gain (Loss) Recognized in Other Comprehensive Income (Loss)							5		$ (7)		2		$ 52
Gain (Loss) Recognized in Earnings (Loss)							3		10		(2)		17
Cash Flow Hedging | Commodity Contract
Derivative [Line Items]
Gain (Loss) Recognized in Other Comprehensive Income (Loss)							5		(9)		(2)		50
Gain (Loss) Recognized in Earnings (Loss)							$ 1		$ 11		$ 2		$ 22
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]							Cost of Goods and Services Sold		Cost of Goods and Services Sold		Cost of Goods and Services Sold		Cost of Goods and Services Sold
Cash Flow Hedging | Commodity Contract | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount		63					$ 63				$ 63				82
Cash Flow Hedging | Foreign Exchange Contract [Member]
Derivative [Line Items]
Gain (Loss) Recognized in Other Comprehensive Income (Loss)							0		$ 2		4		$ 2
Gain (Loss) Recognized in Earnings (Loss)							$ 4		$ 0		$ 2		$ 0
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]							Cost of Goods and Services Sold		Cost of Goods and Services Sold		Cost of Goods and Services Sold		Cost of Goods and Services Sold
Cash Flow Hedging | Foreign Exchange Contract [Member] | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount		27					$ 27				$ 27				$ 49
Cash Flow Hedging | Interest Rate Swap [Member]
Derivative [Line Items]
Gain (Loss) Recognized in Other Comprehensive Income (Loss)							0		$ 0		0		$ 0
Gain (Loss) Recognized in Earnings (Loss)							$ (2)		$ (1)		$ (6)		$ (5)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]							Interest Expense		Interest Expense		Interest Expense		Interest Expense
Fair Value Hedging | Currency Swap
Derivative [Line Items]
Gain (Loss) Recognized in Earnings (Loss)							$ 40	[1]	$ 0	[1]	$ 40		$ 0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax							$ 18	[1]	$ 0	[1]	$ 18		$ 0
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]							Foreign exchange gain (loss), net		Foreign exchange gain (loss), net		Foreign exchange gain (loss), net		Foreign exchange gain (loss), net
Net Investment Hedging
Derivative [Line Items]
Gain (Loss) Recognized in Other Comprehensive Income (Loss)							$ 138		$ 238		$ (16)	[2]	$ 386	[2]
Gain (Loss) Recognized in Earnings (Loss)							0		0		0	[2]	0	[2]
Net Investment Hedging | Currency Swap
Derivative [Line Items]
Gain (Loss) Recognized in Earnings (Loss)							0		0		0	[2]	0	[2]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax							77		90		(16)	[2]	117	[2]
Foreign Currency Denominated Debt | Fair Value Hedging
Derivative [Line Items]
Notional Amount of Nonderivative Instruments	[3]	$ 1,500
Foreign Currency Denominated Debt | Net Investment Hedging
Derivative [Line Items]
Gain (Loss) Recognized in Other Comprehensive Income (Loss)							61		148		0	[2]	269	[2]
Gain (Loss) Recognized in Earnings (Loss)							$ 0		$ 0		$ 0	[2]	$ 0	[2]
Notional Amount of Nonderivative Instruments | €			€ 5,367	€ 5,639
Japanese Notes Due 2029 | Fair Value Hedging | Currency Swap
Derivative [Line Items]
Derivative, notional amount						$ 500
Euro Notes Due 2028 and 2030 | Fair Value Hedging | Currency Swap
Derivative [Line Items]
Derivative, notional amount						$ 1,000
Euro Notes Due 2028
Derivative [Line Items]
Debt instrument, term						5 years
Euro Notes Due 2030
Derivative [Line Items]
Debt instrument, term						7 years
USD Senior Unsecured Notes Due 2027 | Net Investment Hedging | Currency Swap
Derivative [Line Items]
Derivative, notional amount																$ 2,000
USD Senior Unsecured Notes Due 2032 | Net Investment Hedging | Currency Swap
Derivative [Line Items]
Derivative, notional amount																$ 500
Acquisition Notes | Net Investment Hedging
Derivative [Line Items]
Notional Amount of Nonderivative Instruments | €					€ 1,500
[1] In conjunction with the 2023 Offering ( Note 7 ) in August 2023, the Company entered into a cross-currency swap to effectively convert $500 million of the issued notes into a Japanese yen-denominated borrowing at prevailing yen interest rates, maturing on July 15, 2029. The swap qualifies and has been designated as a fair value hedge of the Company's foreign currency exchange rate exposure on the long-term debt of its Japanese yen-denominated subsidiary. Additionally, in conjunction with the 2023 Offering ( Note 7 ) in August 2023, the Company entered into cross-currency swaps to effectively convert $1.0 billion of the issued notes into 5-year and 7-year euro-denominated borrowings at prevailing euro interest rates, maturing on November 15, 2028 and November 15, 2030, respectively. The swaps qualify and have been designated as fair value hedges of the Company's foreign currency exchange rate exposure on the long-term debt of its euro-denominated subsidiary. Concurrently with offering of the Acquisition USD Notes in July 2022 ( Note 7 ), the Company entered into cross-currency swaps to effectively convert $2.0 billion and $500 million of the Acquisition USD Notes into a euro-denominated borrowing at prevailing euro interest rates, maturing on July 15, 2027 and July 15, 2032, respectively. The swaps and €1.5 billion of the Acquisition Euro Notes qualify and have been designated as net investment hedges of the Company's foreign currency exchange rate exposure on the net investments of certain of its euro-denominated subsidiaries. The Company has intercompany loans that are exposed to volatility in currency exchange rates. The Company utilizes cross-currency swaps to hedge these exposures ( Note 12 ).

Derivative Financial Instrume_4

Derivative Financial Instruments (Schedule of Offsetting Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Derivative Assets [Abstract]
Gross amount recognized	$ 187	$ 169
Gross amount offset in the consolidated balance sheets	0	0
Net amount presented in the consolidated balance sheets	187	169
Gross amount not offset in the consolidated balance sheets	44	16
Net amount	$ 143	$ 153
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other assets, Other Assets, Noncurrent	Other assets, Other Assets, Noncurrent

Derivative Financial Instrume_5

Derivative Financial Instruments (Schedule of Offsetting Liabilities) (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Derivative Liabilities [Abstract]
Gross amount recognized	$ 226	$ 189
Gross amount offset in the consolidated balance sheets	0	0
Net amount presented in the consolidated balance sheets	226	189
Gross amount not offset in the consolidated balance sheets	44	16
Net amount	$ 182	$ 173
Derivative liability, statement of financial position [Extensible Enumeration]	Other liabilities, Other liabilities	Other liabilities, Other liabilities

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) € in Millions, $ in Millions		Sep. 30, 2023 USD ($)	Sep. 30, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset		$ 143			$ 153
Commodity swaps		$ (182)			$ (173)
Derivative Asset, Statement of Financial Position [Extensible Enumeration]		Other assets			Other assets
Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]		Other Assets, Noncurrent			Other Assets, Noncurrent
Derivative liability, statement of financial position [Extensible Enumeration]		Other liabilities			Other liabilities
Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]		Other liabilities			Other liabilities
Other Current Assets | Fair Value, Recurring | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure		$ 141			$ 117
Other Current Assets | Fair Value, Recurring | Not Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure		9			9
Other Noncurrent Assets | Fair Value, Recurring | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure		46			52
Other Noncurrent Assets | Fair Value, Recurring | Not Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure		0			0
Other Current Liabilities | Fair Value, Recurring | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure		(46)			(63)
Other Current Liabilities | Fair Value, Recurring | Not Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure		(11)			(3)
Other Noncurrent Liabilities | Fair Value, Recurring | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure		(180)			(126)
Other Noncurrent Liabilities | Fair Value, Recurring | Not Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure		(10)			0
Net Investment Hedging | Foreign Currency Denominated Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional Amount of Nonderivative Instruments | €			€ 5,367	€ 5,639
Cash Flow Hedging | Other Current Assets | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure		2			0
Cash Flow Hedging | Other Noncurrent Assets | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure		0			0
Cash Flow Hedging | Other Current Liabilities | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure		0			0
Cash Flow Hedging | Other Noncurrent Liabilities | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure		0			0
Fair Value Hedging | Foreign Currency Denominated Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional Amount of Nonderivative Instruments	[1]	1,500
Commodity Contract | Cash Flow Hedging | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount		63			82
Commodity Contract | Cash Flow Hedging | Other Current Assets | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset		6			9
Commodity Contract | Cash Flow Hedging | Other Noncurrent Assets | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset		36			39
Commodity Contract | Cash Flow Hedging | Other Current Liabilities | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Commodity swaps		0			(2)
Commodity Contract | Cash Flow Hedging | Other Noncurrent Liabilities | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Commodity swaps		0			0
Currency Swap | Net Investment Hedging | Other Current Assets | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure		91			99
Currency Swap | Net Investment Hedging | Other Noncurrent Assets | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure		0			13
Currency Swap | Net Investment Hedging | Other Current Liabilities | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure		(29)			(58)
Currency Swap | Net Investment Hedging | Other Noncurrent Liabilities | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure		(152)			(126)
Currency Swap | Fair Value Hedging | Other Current Assets | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	[1]	33
Currency Swap | Fair Value Hedging | Other Noncurrent Assets | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	[1]	10
Currency Swap | Fair Value Hedging | Other Current Liabilities | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	[1]	(6)
Currency Swap | Fair Value Hedging | Other Noncurrent Liabilities | Fair Value, Recurring | Designated as Hedging Instrument | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	[1]	(18)
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount		2,098			1,265
Foreign Exchange Contract [Member] | Cash Flow Hedging | Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount		$ 27			$ 49
[1] The Company has intercompany loans that are exposed to volatility in currency exchange rates. The Company utilizes cross-currency swaps to hedge these exposures ( Note 12 ).

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Carrying Values and Fair Values of Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity investments without readily determinable fair values, carrying amount	$ 170	$ 170
Equity investments without readily determinable fair values, fair value	0	0
Insurance contracts in nonqualified trusts, carrying amount	21	22
Insurance contracts in nonqualified trusts, fair value	21	23
Long-term debt, including current installments of long-term debt, carrying amount	13,431	13,953
Long-term debt, including current installments of long-term debt, fair value	13,044	13,419
Cash and cash equivalents	1,357	1,508	$ 9,671	$ 536
Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity investments without readily determinable fair values, fair value	0	0
Insurance contracts in nonqualified trusts, fair value	21	23
Long-term debt, including current installments of long-term debt, fair value	12,894	13,247
Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity investments without readily determinable fair values, fair value	0	0
Insurance contracts in nonqualified trusts, fair value	0	0
Long-term debt, including current installments of long-term debt, fair value	$ 150	$ 172

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - 287 months ended Sep. 30, 2023 € in Millions, $ in Millions	USD ($)	EUR (€)	USD ($)
Loss Contingencies [Line Items]
Unrecorded unconditional purchase obligations			$ 3,900
Unrecorded Unconditional Purchase Obligation, to be Paid, Remainder of Fiscal Year			172
Unrecorded Unconditional Purchase Obligation, to be Paid, Year One			635
Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two			555
Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three			436
Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four			$ 353
Indemnification Agreements Hoechst
Loss Contingencies [Line Items]
Number of divestiture agreements		19	19
Indemnification amount | €		€ 250
Indemnification ceiling amount | €		€ 750
Indemnification percentage exceeding ceiling amount		33.33%	33.33%
Loss contingency accrual, carrying value, payments	$ 110
Indemnification percentage, other		33.33%	33.33%
Divestiture Agreements
Loss Contingencies [Line Items]
Guarantor obligations, maximum exposure			$ 116

Segment Information - Schedule

Segment Information - Schedule of Business Segments (Details) - USD ($) $ in Millions		3 Months Ended				9 Months Ended
		Sep. 30, 2023		Sep. 30, 2022		Sep. 30, 2023		Sep. 30, 2022		Dec. 31, 2022
Segment Reporting Information [Line Items]
Net sales		$ 2,723		$ 2,301		$ 8,371		$ 7,325
Other (charges) gains, net (Note 14)		(17)		(15)		(50)		(15)
Operating profit (loss)		842		308		1,428		1,322
Equity in net earnings (loss) of affiliates		12		73		50		189
Depreciation and amortization		173		100		517		309
Capital expenditures		119	[1]	123	[1]	379	[2]	369	[2]
Goodwill and intangible assets, net		10,935				10,935				$ 11,247
Total assets		25,538				25,538				26,272
Increase (decrease) in accrued capital expenditures		(12)		(16)		(61)		(31)
Engineered Materials
Segment Reporting Information [Line Items]
Net sales		1,528		929		4,743		2,787
Acetyl Chain
Segment Reporting Information [Line Items]
Net sales	[3]	1,195		1,372		3,628		4,538
Operating Segments | Engineered Materials
Segment Reporting Information [Line Items]
Net sales		1,528		929		4,743		2,787
Other (charges) gains, net (Note 14)		(15)		(14)		(44)		(14)
Operating profit (loss)		691	[4]	114		961	[5]	404
Equity in net earnings (loss) of affiliates		8		69		37		171
Depreciation and amortization		111		43		335		134
Capital expenditures		51		34		154		99
Goodwill and intangible assets, net		10,518				10,518				10,826
Total assets		17,478				17,478				20,611
Operating Segments | Acetyl Chain
Segment Reporting Information [Line Items]
Net sales		1,220		1,397		3,703		4,608
Other (charges) gains, net (Note 14)		0		0		(1)		0
Operating profit (loss)		272		312		845		1,243
Equity in net earnings (loss) of affiliates		1		1		4		8
Depreciation and amortization		55		53		163		161
Capital expenditures		44		74		162		231
Goodwill and intangible assets, net		417				417				421
Total assets		5,528				5,528				5,471
Corporate, Non-Segment | Other Activities
Segment Reporting Information [Line Items]
Net sales		0		0		0		0
Other (charges) gains, net (Note 14)		(2)		(1)		(5)		(1)
Operating profit (loss)		(121)		(118)		(378)		(325)
Equity in net earnings (loss) of affiliates		3		3		9		10
Depreciation and amortization		7		4		19		14
Capital expenditures		24		15		63		39
Goodwill and intangible assets, net		0				0				0
Total assets		2,532				2,532				190
Eliminations
Segment Reporting Information [Line Items]
Net sales		(25)	[6]	(25)	[6]	(75)	[7]	(70)	[7]
Other (charges) gains, net (Note 14)		0		0		0		0
Operating profit (loss)		0		0		0		0
Equity in net earnings (loss) of affiliates		0		0		0		0
Depreciation and amortization		0		0		0		0
Capital expenditures		0		0		0		0
Goodwill and intangible assets, net		0				0				0
Total assets		0				0				$ 0
Eliminations | Acetyl Chain
Segment Reporting Information [Line Items]
Net sales		$ 25		$ 25		$ 75		$ 70
[1]Includes a decrease in accrued capital expenditures of $12 million and $16 million for the three months ended September 30, 2023 and 2022, respectively.[2]Includes a decrease in accrued capital expenditures of $61 million and $31 million for the nine months ended September 30, 2023 and 2022, respectively.[3]Excludes intersegment sales of $25 million and $25 million for the three months ended September 30, 2023 and 2022, respectively. Excludes intersegment sales of $75 million and $70 million for the nine months ended September 30, 2023 and 2022, respectively.[4] Includes a $508 million gain related to the formation of the Nutrinova joint venture included in Gain (loss) on disposition of businesses and assets, net in the unaudited interim consolidated statements of operations ( Note 3 ). Includes a $508 million gain related to the formation of the Nutrinova joint venture included in Gain (loss) on disposition of businesses and assets, net in the unaudited interim consolidated statements of operations ( Note 3 ).

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of net sales (Details) - USD ($) $ in Millions		3 Months Ended				9 Months Ended
		Sep. 30, 2023		Sep. 30, 2022		Sep. 30, 2023		Sep. 30, 2022
Revenue, Major Customer [Line Items]
Net sales		$ 2,723		$ 2,301		$ 8,371		$ 7,325
Engineered Materials
Revenue, Major Customer [Line Items]
Net sales		1,528		929		4,743		2,787
Acetyl Chain
Revenue, Major Customer [Line Items]
Net sales	[1]	1,195		1,372		3,628		4,538
Intersegment Eliminations
Revenue, Major Customer [Line Items]
Net sales		(25)	[2]	(25)	[2]	(75)	[3]	(70)	[3]
Intersegment Eliminations | Acetyl Chain
Revenue, Major Customer [Line Items]
Net sales		25		25		75		70
North America | Engineered Materials
Revenue, Major Customer [Line Items]
Net sales		449		292		1,399		865
North America | Acetyl Chain
Revenue, Major Customer [Line Items]
Net sales		366		461		1,092		1,337
Europe and Africa | Engineered Materials
Revenue, Major Customer [Line Items]
Net sales		462		355		1,541		1,112
Europe and Africa | Acetyl Chain
Revenue, Major Customer [Line Items]
Net sales		395		461		1,292		1,598
Asia-Pacific | Engineered Materials
Revenue, Major Customer [Line Items]
Net sales		580		256		1,682		733
Asia-Pacific | Acetyl Chain
Revenue, Major Customer [Line Items]
Net sales		406		401		1,152		1,472
South America | Engineered Materials
Revenue, Major Customer [Line Items]
Net sales		37		26		121		77
South America | Acetyl Chain
Revenue, Major Customer [Line Items]
Net sales		$ 28		$ 49		$ 92		$ 131
[1]Excludes intersegment sales of $25 million and $25 million for the three months ended September 30, 2023 and 2022, respectively. Excludes intersegment sales of $75 million and $70 million for the nine months ended September 30, 2023 and 2022, respectively.[2]Includes intersegment sales primarily related to the Acetyl Chain.[3]Includes intersegment sales primarily related to the Acetyl Chain.

Revenue Recognition Remaining P

Revenue Recognition Remaining Performance Obligations (Details) $ in Millions	Sep. 30, 2023 USD ($)
Revenue, Major Customer [Line Items]
Revenue, remaining performance obligation, amount	$ 1,100
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Revenue, Major Customer [Line Items]
Revenue, remaining performance obligation, amount	$ 156
Revenue, remaining performance obligation, expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Major Customer [Line Items]
Revenue, remaining performance obligation, amount	$ 418
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Major Customer [Line Items]
Revenue, remaining performance obligation, amount	$ 256
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Earnings (Loss) Per Share - Sch

Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Amounts attributable to Celanese Corporation
Earnings (loss) from continuing operations		$ 952	$ 192	$ 1,265	$ 1,134
Earnings (loss) from discontinued operations		(1)	(1)	(3)	(7)
Net earnings (loss)		$ 951	$ 191	$ 1,262	$ 1,127
Weighted average shares - basic (in shares)		108,918,986	108,428,982	108,814,288	108,336,574
Incremental shares attributable to equity awards(1)	[1]	520,500	636,988	523,752	822,258
Weighted average shares - diluted		109,439,486	109,065,970	109,338,040	109,158,832
[1]Excludes options to purchase 219,963 and 0 shares of Common Stock for the three months ended September 30, 2023 and 2022, respectively, and options to purchase 190,651 and 0 shares of Common Stock for the nine months ended September 30, 2023 and 2022, respectively, as their effect would have been antidilutive. Excludes 0 and 181,027 equity award shares for the three months ended September 30, 2023 and 2022, respectively, and 42,998 and 149,272 equity award shares for the nine months ended September 30, 2023 and 2022, respectively, as their effect would have been antidilutive.

Earnings (Loss) Per Share - Nar

Earnings (Loss) Per Share - Narrative (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement, Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	219,963	0	190,651	0
Antidilutive securities excluded from computation of earnings per share, amount	219,963	0	190,651	0
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	0	181,027	42,998	149,272
Antidilutive securities excluded from computation of earnings per share, amount	0	181,027	42,998	149,272

Subsequent Events - Narrative (

Subsequent Events - Narrative (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
	Oct. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Subsequent Event [Line Items]
Plant Office Closures		$ 1	$ 0	$ 1	$ 0
Minimum | Subsequent Event | Uentrop, Germany
Subsequent Event [Line Items]
Business Exit Costs	$ 110
Restructuring and Related Cost, Accelerated Depreciation	75
Plant Office Closures	35
Maximum | Subsequent Event | Uentrop, Germany
Subsequent Event [Line Items]
Business Exit Costs	125
Restructuring and Related Cost, Accelerated Depreciation	85
Plant Office Closures	$ 40